mianserin has been researched along with Depression in 258 studies
Mianserin: A tetracyclic compound with antidepressant effects. It may cause drowsiness and hematological problems. Its mechanism of therapeutic action is not well understood, although it apparently blocks alpha-adrenergic, histamine H1, and some types of serotonin receptors.
mianserin : A dibenzoazepine (specifically 1,2,3,4,10,14b-hexahydrodibenzo[c,f]pyrazino[1,2-a]azepine) methyl-substituted on N-2. Closely related to (and now mostly superseded by) the tetracyclic antidepressant mirtazapinean, it is an atypical antidepressant used in the treatment of depression throughout Europe and elsewhere.
Depression: Depressive states usually of moderate intensity in contrast with MAJOR DEPRESSIVE DISORDER present in neurotic and psychotic disorders.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The goal of this study was to investigate the association and causal relationship between mirtazapine treatment of patients with depression and pancreatitis." | 9.41 | Mirtazapine-induced Acute Pancreatitis in Patients With Depression: A Systematic Review. ( Janković, SM; Kostić, MJ; Milosavljević, MN; Pejčić, AV, 2023) |
| "To evaluate the efficacy and safety of mirtazapine in Japanese patients with fibromyalgia (FM), a parallel-group, randomized, double-blind, placebo-controlled phase IIa study was conducted at 57 sites between November 2012 and February 2014." | 9.22 | Efficacy of mirtazapine for the treatment of fibromyalgia without concomitant depression: a randomized, double-blind, placebo-controlled phase IIa study in Japan. ( Miki, K; Murakami, M; Oka, H; Onozawa, K; Osada, K; Yoshida, S, 2016) |
| "Mirtazapine not only alleviates symptoms associated with dyspepsia and depression linked to FD in patients with weight loss but also significantly increases body weight (mainly the visceral fat in body fat)." | 9.22 | Beneficial effects of antidepressant mirtazapine in functional dyspepsia patients with weight loss. ( Jia, L; Jiang, SM; Liu, J; Shi, MM; Xu, MZ, 2016) |
| " (1) The secondary analyses presented here suggest that there would be value in carrying out a placebo-controlled trial of the clinical effectiveness and cost-effectiveness of mirtazapine in the management of Behavioural and Psychological Symptoms of Dementia." | 9.17 | Study of the use of antidepressants for depression in dementia: the HTA-SADD trial--a multicentre, randomised, double-blind, placebo-controlled trial of the clinical effectiveness and cost-effectiveness of sertraline and mirtazapine. ( Baldwin, R; Ballard, C; Banerjee, S; Bentham, P; Burns, A; Dewey, M; Fox, C; Hellier, J; Holmes, C; Katona, C; Knapp, M; Lawton, C; Lindesay, J; Livingston, G; McCrae, N; Moniz-Cook, E; Murray, J; Nurock, S; O'Brien, J; Orrell, M; Poppe, M; Romeo, R; Thomas, A; Walwyn, R; Wilson, K, 2013) |
| "To evaluate the cost-effectiveness of sertraline and mirtazapine compared with placebo for depression in dementia." | 9.17 | Cost-effectiveness analyses for mirtazapine and sertraline in dementia: randomised controlled trial. ( Baldwin, R; Ballard, C; Banerjee, S; Bentham, P; Burns, A; Dewey, M; Fox, C; Hellier, J; Holmes, C; Katona, C; Knapp, M; Lawton, C; Lindesay, J; Livingston, G; McCrae, N; Moniz-Cook, E; Murray, J; Nurock, S; O'Brien, J; Poppe, M; Romeo, R; Thomas, A; Walwyn, R; Wilson, K, 2013) |
| " Eighteen patients had at least moderate depression before mirtazapine treatment and 8 patients presented mild depressive symptoms." | 9.11 | Open trial of mirtazapine in patients with fibromyalgia. ( Lezanska-Szpera, M; Rybakowski, JK; Samborski, W, 2004) |
| "We assessed the prevalence and associations of symptoms of insomnia in patients with acute ischemic stroke, and evaluated whether mianserin as a sedative antidepressant is beneficial in the treatment of poststroke insomnia." | 9.10 | Complaints of poststroke insomnia and its treatment with mianserin. ( Berg, A; Kaste, M; Lehtihalmes, M; Lönnqvist, J; Lönnqvist, R; Meririnne, E; Palomäki, H, 2003) |
| "(1) To test whether early prophylactic antidepressive treatment by mianserin is able to prevent poststroke depression, and (2) to discover whether mianserin as an antidepressant has any beneficial influence on the outcome of ischaemic stroke." | 9.09 | Prevention of poststroke depression: 1 year randomised placebo controlled double blind trial of mianserin with 6 month follow up after therapy. ( Berg, A; Hares, J; Kaste, M; Lehtihalmes, M; Lönnqvist, J; Lönnqvist, R; Palomäki, H, 1999) |
| "To examine the prophylactic effect of mianserin on depressive episode, 26 patients with recurrent depression were randomly allocated on a double-blind basis to treatment with either inactive placebo (PL group) or mianserin in daily dose of 20-60 mg (MIA group) for 18 months and the frequencies or durations of depressive episode during the treatment were compared between the two groups." | 9.07 | [A controlled study of the prophylactic effect of mianserin and placebo in recurrent depression]. ( Hazama, H; Kamase, H; Kishimoto, A; Kunimoto, N; Mizukawa, R; Tanaka, K, 1993) |
| "Forty-two patients aged between 19 and 70 years (30 women and 12 men) suffering from primary unipolar depression were randomly selected and treated under double-blind conditions with either mianserin (Lantanon; Organon) or clomipramine (Anafranil; Ciba-Geigy) after an initial wash-out period." | 9.05 | Mianserin and clomipramine in the treatment of depression. ( Levin, A, 1982) |
| "A double-blind trial was carried out in 47 patients with depression to compare the effectiveness of 30 mg mianserin, 60 mg mianserin and 50 mg sustained-release amitriptyline, each given as a single dose at night over a period of 4 weeks." | 9.05 | A double-blind controlled trial of mianserin and amitriptyline in depression. ( Mehta, BM; Spear, FG; Whittington, JR, 1980) |
| " In a third trial, mianserin was found to be as effective as diazepam in the treatment of anxiety states in general practice." | 9.04 | Mianserin in the treatment of depressive illness and anxiety states in general practice. ( Murphy, JE, 1978) |
| "The aim of the present review was to assess the evidence on the efficacy and acceptability of mirtazapine compared with other antidepressive agents in the acute-phase treatment of major depression in adults." | 8.87 | Mirtazapine versus other antidepressive agents for depression. ( Barbui, C; Churchill, R; Cipriani, A; Furukawa, TA; Nakagawa, A; Omori, IM; Watanabe, N, 2011) |
| "Available data suggest that mirtazapine is a cost-effective alternative to amitriptyline and fluoxetine for the treatment of depression." | 8.80 | Mirtazapine. A pharmacoeconomic review of its use in depression. ( Foster, RH; Holm, KJ; Jarvis, B, 2000) |
| "This study evaluated the clinical efficacy of mirtazapine and its effect on serum brain-derived neurotrophic factor (BDNF) and tumor necrosis factor-α (TNF-α) levels in patients of major-depressive disorder (MDD) with severe depression." | 7.83 | Effect of Mirtazapine Treatment on Serum Levels of Brain-Derived Neurotrophic Factor and Tumor Necrosis Factor-α in Patients of Major Depressive Disorder with Severe Depression. ( Bhatia, MS; Gupta, K; Gupta, LK; Gupta, R; Tripathi, AK, 2016) |
| " We suspected that these symptoms were related to side effects caused by the milnacipran she was taking for depression, prior to hospitalization." | 7.83 | Probable Serotonin Syndrome and Withdrawal Symptoms Caused by Milnacipran. ( Koshiishi, T; Okuyama, K, 2016) |
| "We conducted a nested case-control study to evaluate the association between risk of cancer and mirtazapine use in depression patients in Taiwan." | 7.79 | Does use of tetracyclic antidepressant-mirtazapine reduce cancer risk in depression patients? ( Chang, SN; Chang, YJ; Kao, CH; Liang, JA; Lin, MC; Muo, CH; Sun, LM; Sung, FC, 2013) |
| " This report presents the beneficial effect of low-dose mirtazapine added onto selective serotonin reuptake inhibitors in the treatment of the symptoms of severe nausea, insomnia and loss of appetite accompanying psychiatric disorders during pregnancy, which is an important problem in clinical practice." | 7.79 | Low-dose mirtazapine added to selective serotonin reuptake inhibitors in pregnant women with major depression or panic disorder including symptoms of severe nausea, insomnia and decreased appetite: three cases. ( Uguz, F, 2013) |
| "We describe a patient originally suffering from a depressive syndrome who developed Stevens-Johnson syndrome after 12 days of treatment with lamotrigine." | 7.75 | Neopterin and C-reactive protein in the course of Stevens-Johnson syndrome: report of a case. ( Bertram, L; Grözinger, M; Liss, Y, 2009) |
| " Recent findings have shown, that adipocytokines leptin and adiponectin might play a role in both depression and MetS." | 7.75 | Leptin, adiponectin, leptin to adiponectin ratio and insulin resistance in depressive women. ( Jachymova, M; Jirak, R; Tvrzicka, E; Vecka, M; Zak, A; Zeman, M, 2009) |
| "Two patients, a 61-year-old man and a 79-year-old woman, developed profound hyponatremia (sodium levels, 112 and 113 mEq/L, respectively) 7 and 10 days after commencement of mirtazapine for symptoms of depression." | 7.74 | Mirtazapine associated with profound hyponatremia: two case reports. ( Cheah, CY; Fegan, PG; Ladhams, B, 2008) |
| "Mirtazapine is known to often provoke restless legs syndrome (RLS)." | 7.74 | Factors potentiating the risk of mirtazapine-associated restless legs syndrome. ( Kim, JM; Kim, SW; Park, KH; Shin, IS; Yoon, JS; Youn, T, 2008) |
| "To evaluate the safety, tolerability and efficacy of mirtazapine in patients with the primary diagnosis of chronic pain and concomitant depression in an open post-marketing surveillance study." | 7.73 | The effect of mirtazapine in patients with chronic pain and concomitant depression. ( Freynhagen, R; Lipfert, P; Muth-Selbach, U; Stevens, MF; Tölle, TR; von Giesen, HJ; Zacharowski, K, 2006) |
| "Shortly after initiation of mirtazapine (a noradrenergic and serotonergic antidepressant) treatment in four patients with parkinsonism, the authors observed the appearance of REM sleep behavior disorder (RBD)." | 7.72 | Mirtazapine induces REM sleep behavior disorder (RBD) in parkinsonism. ( D'Andreamatteo, G; Iacono, D; Luciano, AL; Onofrj, M; Thomas, A, 2003) |
| "Three patients with dementia and depression complicated by weight loss, insomnia, and anxiety were treated with mirtazapine at an outpatient memory loss clinic of a university hospital." | 7.71 | Mirtazapine for treatment of depression and comorbidities in Alzheimer disease. ( Brady, SR; Raji, MA, 2001) |
| "To document a case of serotonin syndrome (SS) associated with mirtazapine monotherapy, review the previously reported cases of SS associated with this tetracyclic antidepressant, and discuss the possible pathogenic mechanisms leading to this serious adverse drug reaction." | 7.71 | Severe serotonin syndrome induced by mirtazapine monotherapy. ( González-Macías, J; Hernández, JL; Infante, J; Ramos, FJ; Rebollo, M, 2002) |
| "This study modelled the economic impact of mirtazapine, compared to amitriptyline and fluoxetine, in the management of moderate and severe depression in the UK, as well as the costs related to discontinuation of antidepressant treatment." | 7.70 | Economic impact of using mirtazapine compared to amitriptyline and fluoxetine in the treatment of moderate and severe depression in the UK. ( Borghi, J; Guest, JF, 2000) |
| " To further investigate a previous postulate that increased serotonergic activity may cause depression, the effects of chronic mianserin administration on 5-HT, its metabolites, and the subtypes of 5-HT receptors were studied." | 7.69 | Effects of chronic mianserin administration on serotonin metabolism and receptors in the 5-hydroxytryptophan depression model. ( Akiyoshi, J; Kuranaga, H; Mizobe, Y; Nagayama, H; Nakamura, M; Tsuchiyama, K, 1994) |
| "This study was designed to validate a novel animal model of depression by testing the curative effects of the atypical antidepressant mianserin." | 7.69 | Curative effects of the atypical antidepressant mianserin in the chronic mild stress-induced anhedonia model of depression. ( Bourson, A; Jenck, F; Martin, JR; Moreau, JL; Mortas, P, 1994) |
| " Imipramine and mianserine potentiated amphetamine-induced anorexia both after acute administration or after prolonged previous treatment with each drug." | 7.68 | Lack of tolerance to imipramine or mianserine in two animal models of depression. ( Barros, HM; Tannhauser, M; Wainstein, M, 1990) |
| "Acute pretreatment with clinically equivalent doses of antidepressive drugs has been observed to block D,L-5-hydroxytryptophan (5-HTP) induced behavioral depression in rats working on a food-reinforced operant schedule." | 7.67 | Postsynaptic serotonergic blockade following chronic antidepressive treatment with trazodone in an animal model of depression. ( Aprison, MH; Hendrie, HC; Hingtgen, JN, 1984) |
| "The introduction of two tricyclic compounds (iprindole and mianserin) that are reported to have antidepressant properties but to be relatively devoid of effects on central amine neurotransmitter systems has raised questions about the amine hypothesis of depression and about the mechanism of action of tricyclics in general." | 7.66 | Novel antidepressants and the biogenic amine hypothesis of depression. The case for iprindole and mianserin. ( Goodwin, FK; Zis, AP, 1979) |
| "People with depression are usually managed in primary care and antidepressants are often the first-line treatment, but only one third of patients respond fully to a single antidepressant." | 6.82 | Mirtazapine added to selective serotonin reuptake inhibitors for treatment-resistant depression in primary care (MIR trial): study protocol for a randomised controlled trial. ( Anderson, IM; Campbell, J; Chew-Graham, C; Davies, S; Dickens, C; Gilbody, S; Hollingworth, W; Kessler, D; Lewis, G; Macleod, U; Peters, TJ; Tallon, D; Wiles, N, 2016) |
| "Depression is common in schizophrenia and worsens its course." | 6.76 | Add-on mirtazapine improves depressive symptoms in schizophrenia: a double-blind randomized placebo-controlled study with an open-label extension phase. ( Burkin, M; Joffe, G; Joffe, M; Stenberg, JH; Tchoukhine, E; Terevnikov, V; Tiihonen, J, 2011) |
| " Maximum flexibility of the dosage of mirtazapine was allowed, and clinical assessments included MADRS, CGI, vital signs and spontaneous reporting of adverse events." | 6.72 | Mirtazapine naturalistic depression study (in Sweden)--MINDS(S): clinical efficacy and safety. ( Ahlner, J; Bengtsson, F; Dahl, ML; Odén, A; Prochazka, J; Sjödin, I; Wålinder, J, 2006) |
| "Mirtazapine is an effective treatment for major depression in perimenopausal and postmenopausal women whose depression precedes ERT use and does not respond to ERT or whose depression develops after ERT is initiated." | 6.70 | An open trial of mirtazapine in menopausal women with depression unresponsive to estrogen replacement therapy. ( Cohen, LS; Groninger, H; Joffe, H; Nonacs, R; Soares, C; Soares, CN, 2001) |
| "Mood depression was evaluated at 0, 4 and 8 weeks by using Zung's Self-Rating Depression Scale and Hamilton Rating Scale for Depression." | 6.67 | Chronic tension-type headache, mood depression and serotonin: therapeutic effects of fluvoxamine and mianserine. ( Bolino, F; Di Cicco, L; Manna, V, 1994) |
| "Mianserin was given at a dose of 30 mg for the first 7 days followed by 60 mg daily for the remaining 5 weeks." | 6.66 | The drug treatment of depression in general practice: a comparison of nocte administration of trazodone with mianserin, dothiepin and amitriptyline. ( Blacker, R; Chapman, N; Davey, A; Shanks, NJ, 1988) |
| "Depression is a major complication of cancer." | 6.66 | Efficacy and safety of mianserin in the treatment of depression of women with cancer. ( Costa, D; Mogos, I; Toma, T, 1985) |
| " The dosage for the first week was 25 mg t." | 6.64 | A comparative clinical trial of mianserin (Norval) and amitriptyline in the treatment of depression in general practice. ( Bridgman, KM; Murphy, JE, 1978) |
| " After one year, the dosage of mianserin was increased to 30 mg t." | 6.64 | Mianserin and lithium in the prophylaxis of depression. ( Bailey, J; Coppen, A; Ghose, K; Peet, M; Rao, R, 1978) |
| "Mirtazapine has demonstrated superior tolerability to the tricyclic antidepressants and trazodone, primarily on account of its relative absence of anticholinergic, adrenergic and serotonin-related adverse effects, in particular gastrointestinal adverse effects and sexual dysfunction." | 6.40 | A risk-benefit assessment of mirtazapine in the treatment of depression. ( Kasper, S; Praschak-Rieder, N; Tauscher, J; Wolf, R, 1997) |
| " The goal of this study was to investigate the association and causal relationship between mirtazapine treatment of patients with depression and pancreatitis." | 5.41 | Mirtazapine-induced Acute Pancreatitis in Patients With Depression: A Systematic Review. ( Janković, SM; Kostić, MJ; Milosavljević, MN; Pejčić, AV, 2023) |
| "Depression is a common problem in elderly patients and frequently is treated with antidepressants." | 5.33 | Recurrent hyponatremia associated with citalopram and mirtazapine. ( Akcay, A; Bavbek, N; Kargili, A; Kaya, A, 2006) |
| "Taurine has been known to be related to certain modifications of the immune system." | 5.32 | Taurine concentration in human blood peripheral lymphocytes: major depression and treatment with the antidepressant mirtazapine. ( Baccichet, E; Carreira, I; Lima, L; Obregón, F; Peña, S; Urbina, M, 2003) |
| "To evaluate the efficacy and safety of mirtazapine in Japanese patients with fibromyalgia (FM), a parallel-group, randomized, double-blind, placebo-controlled phase IIa study was conducted at 57 sites between November 2012 and February 2014." | 5.22 | Efficacy of mirtazapine for the treatment of fibromyalgia without concomitant depression: a randomized, double-blind, placebo-controlled phase IIa study in Japan. ( Miki, K; Murakami, M; Oka, H; Onozawa, K; Osada, K; Yoshida, S, 2016) |
| "Mirtazapine not only alleviates symptoms associated with dyspepsia and depression linked to FD in patients with weight loss but also significantly increases body weight (mainly the visceral fat in body fat)." | 5.22 | Beneficial effects of antidepressant mirtazapine in functional dyspepsia patients with weight loss. ( Jia, L; Jiang, SM; Liu, J; Shi, MM; Xu, MZ, 2016) |
| " (1) The secondary analyses presented here suggest that there would be value in carrying out a placebo-controlled trial of the clinical effectiveness and cost-effectiveness of mirtazapine in the management of Behavioural and Psychological Symptoms of Dementia." | 5.17 | Study of the use of antidepressants for depression in dementia: the HTA-SADD trial--a multicentre, randomised, double-blind, placebo-controlled trial of the clinical effectiveness and cost-effectiveness of sertraline and mirtazapine. ( Baldwin, R; Ballard, C; Banerjee, S; Bentham, P; Burns, A; Dewey, M; Fox, C; Hellier, J; Holmes, C; Katona, C; Knapp, M; Lawton, C; Lindesay, J; Livingston, G; McCrae, N; Moniz-Cook, E; Murray, J; Nurock, S; O'Brien, J; Orrell, M; Poppe, M; Romeo, R; Thomas, A; Walwyn, R; Wilson, K, 2013) |
| "To evaluate the cost-effectiveness of sertraline and mirtazapine compared with placebo for depression in dementia." | 5.17 | Cost-effectiveness analyses for mirtazapine and sertraline in dementia: randomised controlled trial. ( Baldwin, R; Ballard, C; Banerjee, S; Bentham, P; Burns, A; Dewey, M; Fox, C; Hellier, J; Holmes, C; Katona, C; Knapp, M; Lawton, C; Lindesay, J; Livingston, G; McCrae, N; Moniz-Cook, E; Murray, J; Nurock, S; O'Brien, J; Poppe, M; Romeo, R; Thomas, A; Walwyn, R; Wilson, K, 2013) |
| " Eighteen patients had at least moderate depression before mirtazapine treatment and 8 patients presented mild depressive symptoms." | 5.11 | Open trial of mirtazapine in patients with fibromyalgia. ( Lezanska-Szpera, M; Rybakowski, JK; Samborski, W, 2004) |
| "We assessed the prevalence and associations of symptoms of insomnia in patients with acute ischemic stroke, and evaluated whether mianserin as a sedative antidepressant is beneficial in the treatment of poststroke insomnia." | 5.10 | Complaints of poststroke insomnia and its treatment with mianserin. ( Berg, A; Kaste, M; Lehtihalmes, M; Lönnqvist, J; Lönnqvist, R; Meririnne, E; Palomäki, H, 2003) |
| " We sought to determine if the APOE epsilon4 allele influences response in geriatric depression to mirtazapine and paroxetine, two frequently prescribed antidepressants." | 5.10 | The apolipoprotein E epsilon4 allele and antidepressant efficacy in cognitively intact elderly depressed patients. ( Kremer, C; Murphy, GM; Rodrigues, H; Schatzberg, AF, 2003) |
| "(1) To test whether early prophylactic antidepressive treatment by mianserin is able to prevent poststroke depression, and (2) to discover whether mianserin as an antidepressant has any beneficial influence on the outcome of ischaemic stroke." | 5.09 | Prevention of poststroke depression: 1 year randomised placebo controlled double blind trial of mianserin with 6 month follow up after therapy. ( Berg, A; Hares, J; Kaste, M; Lehtihalmes, M; Lönnqvist, J; Lönnqvist, R; Palomäki, H, 1999) |
| "To examine the prophylactic effect of mianserin on depressive episode, 26 patients with recurrent depression were randomly allocated on a double-blind basis to treatment with either inactive placebo (PL group) or mianserin in daily dose of 20-60 mg (MIA group) for 18 months and the frequencies or durations of depressive episode during the treatment were compared between the two groups." | 5.07 | [A controlled study of the prophylactic effect of mianserin and placebo in recurrent depression]. ( Hazama, H; Kamase, H; Kishimoto, A; Kunimoto, N; Mizukawa, R; Tanaka, K, 1993) |
| "This 6-week, double-blind, randomised parallel group study was carried out to assess the efficacy and tolerability of 150 mg trazodone nocte and 30-60 mg mianserin nocte in the treatment of depression in general practice." | 5.06 | The efficacy and residual effects of trazodone (150 mg nocte) and mianserin in the treatment of depressed general practice patients. ( Davey, A; Moon, CA, 1988) |
| " Forty-six patients with moderate to severe degrees of depression were treated at random with mianserin or diazepam." | 5.04 | Comparative double-blind trial of mianserin hydrochloride (Organon GB94) and diazepam in patients with depressive illness. ( Niaz, U; Russell, GF; Slade, PD; Wakeling, A, 1978) |
| " In a third trial, mianserin was found to be as effective as diazepam in the treatment of anxiety states in general practice." | 5.04 | Mianserin in the treatment of depressive illness and anxiety states in general practice. ( Murphy, JE, 1978) |
| "Limited evidence suggests that for certain elderly patients, mirtazapine may be preferable to sertraline for treatment of depression." | 4.89 | Sertraline and mirtazapine as geriatric antidepressants. ( Bhogle, M; Holland, J, 2013) |
| "The aim of the present review was to assess the evidence on the efficacy and acceptability of mirtazapine compared with other antidepressive agents in the acute-phase treatment of major depression in adults." | 4.87 | Mirtazapine versus other antidepressive agents for depression. ( Barbui, C; Churchill, R; Cipriani, A; Furukawa, TA; Nakagawa, A; Omori, IM; Watanabe, N, 2011) |
| "Available data suggest that mirtazapine is a cost-effective alternative to amitriptyline and fluoxetine for the treatment of depression." | 4.80 | Mirtazapine. A pharmacoeconomic review of its use in depression. ( Foster, RH; Holm, KJ; Jarvis, B, 2000) |
| " Does this mean that the SSRIs, moclobemide and mianserin should be the treatment of first choice for depression? On balance, the evidence presented in this article would suggest rather that the new agents and TCAs should all be considered first-line agents." | 4.79 | The management of depression. Part 2. The place of the new antidepressants. ( Mitchell, MS; Mitchell, PB, 1994) |
| "Mianserin is a tetracyclic compound advocated for the treatment of depressive illness and depression associated with anxiety." | 4.75 | Mianserin: a review of its pharmacological properties and therapeutic efficacy in depressive illness. ( Avery, GS; Brogden, RN; Heel, RC; Speight, TM, 1978) |
| "This study evaluated the clinical efficacy of mirtazapine and its effect on serum brain-derived neurotrophic factor (BDNF) and tumor necrosis factor-α (TNF-α) levels in patients of major-depressive disorder (MDD) with severe depression." | 3.83 | Effect of Mirtazapine Treatment on Serum Levels of Brain-Derived Neurotrophic Factor and Tumor Necrosis Factor-α in Patients of Major Depressive Disorder with Severe Depression. ( Bhatia, MS; Gupta, K; Gupta, LK; Gupta, R; Tripathi, AK, 2016) |
| " We suspected that these symptoms were related to side effects caused by the milnacipran she was taking for depression, prior to hospitalization." | 3.83 | Probable Serotonin Syndrome and Withdrawal Symptoms Caused by Milnacipran. ( Koshiishi, T; Okuyama, K, 2016) |
| "To assess whether the use of selective serotonin reuptake inhibitors (SSRIs), tricyclic antidepressants, mirtazapine, venlafaxine or other antidepressants is associated with late elective termination of pregnancy." | 3.81 | Use of antidepressants and association with elective termination of pregnancy: population based case-control study. ( Artama, M; Engeland, A; Furu, K; Gissler, M; Haglund, B; Kieler, H; Malm, H; Nørgaard, M; Stephansson, O; Valdimarsdottir, U; Zoega, H, 2015) |
| " The purpose of our study was to determine if antidepressants improve depression via the NO pathway using an acute depressive rat model induced by L-arginine (AR)." | 3.81 | Antidepressant action via the nitric oxide system: A pilot study in an acute depressive model induced by arginin. ( Abe, M; Mori, Y; Nakata, S; Ochi, S; Ueno, S; Yamazaki, K; Yoshino, Y, 2015) |
| " Authors report a case of a 65-year old male patient who was treated with venlafaxine-mirtazapine combination for recurrent depression." | 3.79 | [Antidepressant treatment associated hyponatremia -- case report]. ( Bognár, Z; Gazdag, G; Vonyik, G, 2013) |
| "We conducted a nested case-control study to evaluate the association between risk of cancer and mirtazapine use in depression patients in Taiwan." | 3.79 | Does use of tetracyclic antidepressant-mirtazapine reduce cancer risk in depression patients? ( Chang, SN; Chang, YJ; Kao, CH; Liang, JA; Lin, MC; Muo, CH; Sun, LM; Sung, FC, 2013) |
| " This report presents the beneficial effect of low-dose mirtazapine added onto selective serotonin reuptake inhibitors in the treatment of the symptoms of severe nausea, insomnia and loss of appetite accompanying psychiatric disorders during pregnancy, which is an important problem in clinical practice." | 3.79 | Low-dose mirtazapine added to selective serotonin reuptake inhibitors in pregnant women with major depression or panic disorder including symptoms of severe nausea, insomnia and decreased appetite: three cases. ( Uguz, F, 2013) |
| "Several clinical reports have postulated a beneficial effect of the addition of a low dose of risperidone to the ongoing treatment with antidepressants in treatment-resistant depression." | 3.78 | Effect of co-treatment with fluoxetine or mirtazapine and risperidone on the active behaviors and plasma corticosterone concentration in rats subjected to the forced swim test. ( Gądek-Michalska, A; Kabziński, M; Rachwalska, P; Rogóż, Z; Sadaj, W, 2012) |
| "The purpose of this study was to elucidate the mechanism underlying the clinical efficacy of mirtazapine-perospirone combination therapy for treatment-resistant depression in a rat model." | 3.77 | Mirtazapine in combination with perospirone synergistically enhances dopamine release in the rat prefrontal cortex via 5-HT1A receptor activation. ( Morita, M; Nakayama, K, 2011) |
| "Mirtazapine is a new antidepressant used in last years, however experience with it during pregnancy is unsatisfactory on the present." | 3.76 | Embryotoxicity of mirtazapine: a study using Chick Embryotoxicity Screening Test. ( Hubickova, L; Kostalova, J; Manakova, E; Zemanova, Z, 2010) |
| "We describe a patient originally suffering from a depressive syndrome who developed Stevens-Johnson syndrome after 12 days of treatment with lamotrigine." | 3.75 | Neopterin and C-reactive protein in the course of Stevens-Johnson syndrome: report of a case. ( Bertram, L; Grözinger, M; Liss, Y, 2009) |
| " Recent findings have shown, that adipocytokines leptin and adiponectin might play a role in both depression and MetS." | 3.75 | Leptin, adiponectin, leptin to adiponectin ratio and insulin resistance in depressive women. ( Jachymova, M; Jirak, R; Tvrzicka, E; Vecka, M; Zak, A; Zeman, M, 2009) |
| "Two patients, a 61-year-old man and a 79-year-old woman, developed profound hyponatremia (sodium levels, 112 and 113 mEq/L, respectively) 7 and 10 days after commencement of mirtazapine for symptoms of depression." | 3.74 | Mirtazapine associated with profound hyponatremia: two case reports. ( Cheah, CY; Fegan, PG; Ladhams, B, 2008) |
| "Mirtazapine is known to often provoke restless legs syndrome (RLS)." | 3.74 | Factors potentiating the risk of mirtazapine-associated restless legs syndrome. ( Kim, JM; Kim, SW; Park, KH; Shin, IS; Yoon, JS; Youn, T, 2008) |
| "To evaluate the safety, tolerability and efficacy of mirtazapine in patients with the primary diagnosis of chronic pain and concomitant depression in an open post-marketing surveillance study." | 3.73 | The effect of mirtazapine in patients with chronic pain and concomitant depression. ( Freynhagen, R; Lipfert, P; Muth-Selbach, U; Stevens, MF; Tölle, TR; von Giesen, HJ; Zacharowski, K, 2006) |
| "Shortly after initiation of mirtazapine (a noradrenergic and serotonergic antidepressant) treatment in four patients with parkinsonism, the authors observed the appearance of REM sleep behavior disorder (RBD)." | 3.72 | Mirtazapine induces REM sleep behavior disorder (RBD) in parkinsonism. ( D'Andreamatteo, G; Iacono, D; Luciano, AL; Onofrj, M; Thomas, A, 2003) |
| "Three patients with dementia and depression complicated by weight loss, insomnia, and anxiety were treated with mirtazapine at an outpatient memory loss clinic of a university hospital." | 3.71 | Mirtazapine for treatment of depression and comorbidities in Alzheimer disease. ( Brady, SR; Raji, MA, 2001) |
| "To document a case of serotonin syndrome (SS) associated with mirtazapine monotherapy, review the previously reported cases of SS associated with this tetracyclic antidepressant, and discuss the possible pathogenic mechanisms leading to this serious adverse drug reaction." | 3.71 | Severe serotonin syndrome induced by mirtazapine monotherapy. ( González-Macías, J; Hernández, JL; Infante, J; Ramos, FJ; Rebollo, M, 2002) |
| "This study modelled the economic impact of mirtazapine, compared to amitriptyline and fluoxetine, in the management of moderate and severe depression in the UK, as well as the costs related to discontinuation of antidepressant treatment." | 3.70 | Economic impact of using mirtazapine compared to amitriptyline and fluoxetine in the treatment of moderate and severe depression in the UK. ( Borghi, J; Guest, JF, 2000) |
| "In two women with depression a reduction in hot flushes was noticed by serendipity during treatment with mirtazapine 15-30 mg/daily." | 3.70 | Treatment of hot flushes with mirtazapine: four case reports. ( Berendsen, HH; Schweitzer, DH; Waldinger, MD, 2000) |
| " To further investigate a previous postulate that increased serotonergic activity may cause depression, the effects of chronic mianserin administration on 5-HT, its metabolites, and the subtypes of 5-HT receptors were studied." | 3.69 | Effects of chronic mianserin administration on serotonin metabolism and receptors in the 5-hydroxytryptophan depression model. ( Akiyoshi, J; Kuranaga, H; Mizobe, Y; Nagayama, H; Nakamura, M; Tsuchiyama, K, 1994) |
| "We have previously found that repeated phencyclidine (PCP) treatment enhances the immobility induced by forced swimming and suggested that this behavioral change could be used as a model of the negative symptoms, particularly depression, of schizophrenia." | 3.69 | Effects of antidepressants on phencyclidine-induced enhancement of immobility in a forced swimming test in mice. ( Furukawa, H; Mamiya, T; Nabeshima, T; Noda, Y, 1997) |
| " Imipramine and mianserine potentiated amphetamine-induced anorexia both after acute administration or after prolonged previous treatment with each drug." | 3.68 | Lack of tolerance to imipramine or mianserine in two animal models of depression. ( Barros, HM; Tannhauser, M; Wainstein, M, 1990) |
| "Acute pretreatment with clinically equivalent doses of antidepressive drugs has been observed to block D,L-5-hydroxytryptophan (5-HTP) induced behavioral depression in rats working on a food-reinforced operant schedule." | 3.67 | Postsynaptic serotonergic blockade following chronic antidepressive treatment with trazodone in an animal model of depression. ( Aprison, MH; Hendrie, HC; Hingtgen, JN, 1984) |
| "To further test the new hypersensitive postsynaptic serotonin (5-HT) receptor theory of depression bases on or animal model, it was necessary to demonstrate that some of the currently used antidepressive drugs can block D,L-5-hydroxytryptophan (5-HTP) induced depression acting through postsynaptic rather than presynaptic mechanisms." | 3.66 | Postsynaptic action by four antidepressive drugs in an animal model of depression. ( Aprison, MH; Hingtgen, JN; Nagayama, H, 1981) |
| "The introduction of two tricyclic compounds (iprindole and mianserin) that are reported to have antidepressant properties but to be relatively devoid of effects on central amine neurotransmitter systems has raised questions about the amine hypothesis of depression and about the mechanism of action of tricyclics in general." | 3.66 | Novel antidepressants and the biogenic amine hypothesis of depression. The case for iprindole and mianserin. ( Goodwin, FK; Zis, AP, 1979) |
| "(1) Org GB94 (Mianserin hydrochloride), a new tetracyclic antidepressant, was administered to 21 patients with depression or with depressive states." | 3.66 | Clinical experience with Org GB94 (mianserin hydrochloride), a new tetracyclic antidepressant. ( Inanaga, K; Nakano, T; Okamoto, K, 1978) |
| "People with depression are usually managed in primary care and antidepressants are often the first-line treatment, but only one third of patients respond fully to a single antidepressant." | 2.82 | Mirtazapine added to selective serotonin reuptake inhibitors for treatment-resistant depression in primary care (MIR trial): study protocol for a randomised controlled trial. ( Anderson, IM; Campbell, J; Chew-Graham, C; Davies, S; Dickens, C; Gilbody, S; Hollingworth, W; Kessler, D; Lewis, G; Macleod, U; Peters, TJ; Tallon, D; Wiles, N, 2016) |
| "Depression is common in schizophrenia and worsens its course." | 2.76 | Add-on mirtazapine improves depressive symptoms in schizophrenia: a double-blind randomized placebo-controlled study with an open-label extension phase. ( Burkin, M; Joffe, G; Joffe, M; Stenberg, JH; Tchoukhine, E; Terevnikov, V; Tiihonen, J, 2011) |
| "Mirtazapine is an established antidepressant with well-documented efficacy demonstrated in controlled clinical trials." | 2.74 | Efficacy, tolerability, and preference of mirtazapine orally disintegrating tablets in depressed patients: a 17-week naturalistic study in Lithuania. ( Adomaitiene, V; Danileviciūte, V; Fokas, V; Gumbrevicius, G; Sveikata, A; Sveikatiene, R, 2009) |
| " Maximum flexibility of the dosage of mirtazapine was allowed, and clinical assessments included MADRS, CGI, vital signs and spontaneous reporting of adverse events." | 2.72 | Mirtazapine naturalistic depression study (in Sweden)--MINDS(S): clinical efficacy and safety. ( Ahlner, J; Bengtsson, F; Dahl, ML; Odén, A; Prochazka, J; Sjödin, I; Wålinder, J, 2006) |
| "Depression is associated with stroke severity and functional impairment, and with the male sex at 18 months." | 2.71 | Poststroke depression: an 18-month follow-up. ( Berg, A; Kaste, M; Lehtihalmes, M; Lönnqvist, J; Palomäki, H, 2003) |
| "Mirtazapine is an effective treatment for major depression in perimenopausal and postmenopausal women whose depression precedes ERT use and does not respond to ERT or whose depression develops after ERT is initiated." | 2.70 | An open trial of mirtazapine in menopausal women with depression unresponsive to estrogen replacement therapy. ( Cohen, LS; Groninger, H; Joffe, H; Nonacs, R; Soares, C; Soares, CN, 2001) |
| "Imipramine was more effective against the clusters related to core symptoms of depression: "depression and guilt", "retardation", and "melancholia", respectively." | 2.69 | Depressed in-patients respond differently to imipramine and mirtazapine. ( Bruijn, JA; Moleman, P; Mulder, PG; van den Broek, WW, 1999) |
| " Adding risperidone to mirtazapine probably does not necessitate a change of the dosage of either drug, but more extensive investigations are needed." | 2.69 | Lack of drug interactions between mirtazapine and risperidone in psychiatric patients: a pilot study. ( Doorschot, CH; Loonen, AJ; Oostelbos, MC; Sitsen, JM, 1999) |
| "S-Desmethylmianserin was in most of the samples present in concentrations of < 10 nM (limit of detection)." | 2.68 | Enantioselective determination of mianserin and its desmethyl metabolite in plasma during treatment of depressed Japanese patients. ( Bertilsson, L; Fukushima, Y; Kaneko, S; Mihara, K; Otani, K; Tybring, G, 1995) |
| "Mood depression was evaluated at 0, 4 and 8 weeks by using Zung's Self-Rating Depression Scale and Hamilton Rating Scale for Depression." | 2.67 | Chronic tension-type headache, mood depression and serotonin: therapeutic effects of fluvoxamine and mianserine. ( Bolino, F; Di Cicco, L; Manna, V, 1994) |
| "Fluvoxamine and mianserin were both shown to be effective in the treatment of depressive illness." | 2.67 | The effects of psychomotor performance of fluvoxamine versus mianserin in depressed patients in general practice. ( Jesinger, DK; Moon, CA, 1991) |
| "Mianserin was given at a dose of 30 mg for the first 7 days followed by 60 mg daily for the remaining 5 weeks." | 2.66 | The drug treatment of depression in general practice: a comparison of nocte administration of trazodone with mianserin, dothiepin and amitriptyline. ( Blacker, R; Chapman, N; Davey, A; Shanks, NJ, 1988) |
| "Mood disturbances accompanying migraine syndromes suggest a mode of action of such a class of drugs." | 2.66 | Antidepressant drugs and migraine. ( Agnoli, A; Manna, V; Martucci, N, 1985) |
| "Depression is a major complication of cancer." | 2.66 | Efficacy and safety of mianserin in the treatment of depression of women with cancer. ( Costa, D; Mogos, I; Toma, T, 1985) |
| "Mianserin was significantly superior to diazepam in antidepressant efficacy from day 14 to the end of the trial, as measured by the Hamilton Rating Scale for Depression and the Beck Self-Rating Scale, and at day 28 as measured by the Clinical Global Impression." | 2.65 | A double-blind group comparative trial of mianserin and diazepam in depressed outpatients. ( Hamouz, W; Pinder, RM; Stulemeijer, SM, 1980) |
| "3." | 2.64 | Effect of mianserin hydrochloride on peripheral uptake mechanisms for noradrenaline and 5-hydroxytryptamine in man. ( Coppen, A; Ghose, K; Swade, C; Wood, K, 1978) |
| " There was no significant difference in antidepressant effect between the two dosage regimens in either patient group measured using Hamilton Rating Scale (HRS), the Beck Self-Rating Inventory (BSRI) and the new Montgomery and Asberg Depression Scale (MADS)." | 2.64 | Relationship between mianserin plasma levels and antidepressant effect in a double-blind trial comparing a single night-time and divided daily dose regimens. ( McAuley, R; Montgomery, DB; Montgomery, S, 1978) |
| "mianserin daily, and were rated on the Hamilton Rating Scale and on the Wakefield Self-Assessment Inventory on day 0, before starting therapy, and on days 7 and 28 of their treatment." | 2.64 | Mianserin hydrochloride: a new anti-depressant drug. ( Bennie, EH, 1978) |
| " After one year, the dosage of mianserin was increased to 30 mg t." | 2.64 | Mianserin and lithium in the prophylaxis of depression. ( Bailey, J; Coppen, A; Ghose, K; Peet, M; Rao, R, 1978) |
| "Amitriptyline and mianserin were compared in a double-blind trial." | 2.64 | Mianserin versus amitriptyline. A double-blind-trial evaluated by the AMP system. ( Bente, D; Bohacek, N; Brändli, A; Feder, J; Fleischhauer, J; Helmchen, H; Mihovilović, M; Müller-Oerlinghausen, B; Vogel, HP; Walcher, W, 1976) |
| "(Mianserin was compared with Amitriptyline in a double-blind-trial)." | 2.64 | [New diagnostic strategies in psychiatry by means of video-technique. I. The use of time-blind video analysis for the evaluation of antidepressant drug trials (author's transl)]. ( Busch, H; Renfordt, E, 1976) |
| "Buspirone has an indication for generalized anxiety disorder though studies show only a minimal benefit." | 2.53 | Empirically Supported Use of Psychiatric Medications in Adolescents and Adults with IBD. ( Bielefeldt, K; Szigethy, E; Thorkelson, G, 2016) |
| "Such approach to treatment of insomnia in depressed patients protects them against dependence on hypnotic drugs." | 2.47 | [The effects of antidepressants on sleep in depressed patients with particular reference to trazodone in comparison to agomelatine, amitriptyline, doxepin, mianserine and mirtazapine]. ( Wichniak, A; Wierzbicka, A, 2011) |
| "Mirtazapine is an effective antidepressant with unique and special mechanism of action characterized by high response and remission rates, relatively early onest of action and favourable side-effect profile." | 2.45 | [Mirtazapine--pharmacologic action and clinical advantages]. ( Purebl, G; Rihmer, Z, 2009) |
| "Emphasis is given to the treatment of depression and how the potential of one pure enantiomer-escitalopram, the S-enantiomer of the selective serotonin reuptake inhibitor citalopram-appears to be fulfilling its preclinical promise in the clinic." | 2.41 | Enantiomers' potential in psychopharmacology--a critical analysis with special emphasis on the antidepressant escitalopram. ( Baumann, P; Eap, CB; Zullino, DF, 2002) |
| "Direct costs for treating depression, i." | 2.41 | [Treatment of depression and cost efficiency. The cost of a tablet is a poor indicator seen from a socioeconomic perspective]. ( Häggström, L; Nordling, S; Norinder, A, 2000) |
| "Mirtazapine has demonstrated superior tolerability to the tricyclic antidepressants and trazodone, primarily on account of its relative absence of anticholinergic, adrenergic and serotonin-related adverse effects, in particular gastrointestinal adverse effects and sexual dysfunction." | 2.40 | A risk-benefit assessment of mirtazapine in the treatment of depression. ( Kasper, S; Praschak-Rieder, N; Tauscher, J; Wolf, R, 1997) |
| " With chronic administration each of the antidepressants produced effects which could potentially interfere with CRF function in the LC." | 2.38 | Pharmacology of locus coeruleus spontaneous and sensory-evoked activity. ( Curtis, AL; Valentino, RJ, 1991) |
| " Mianserin and mirtazapine (separately) induced dose-dependent antinociception, each one yielding a biphasic dose-response curve, and they were antagonized by naloxone." | 1.91 | Treatment-Resistant Depression (TRD): Is the Opioid System Involved? ( Keidan, L; Pick, CG; Schreiber, S, 2023) |
| "Depression is prevalent in primary biliary cholangitis (PBC) patients." | 1.48 | The impact of depression and antidepressant usage on primary biliary cholangitis clinical outcomes. ( Almishri, W; Frolkis, AD; Kaplan, GG; Patten, S; Shaheen, AA; Swain, MG; Vallerand, I, 2018) |
| "Mirtazapine is a widely-used antidepressant with a multimodal mechanism of action." | 1.48 | Tachyphylaxis to the Sedative Action of Mirtazapine. ( Papazisis, G; Siafis, S; Tzachanis, D, 2018) |
| "Fluoxetine was the reference treatment option in the medication models." | 1.39 | Influence of body mass index on the choice of therapy for depression and follow-up care. ( Arterburn, D; Bogart, A; Boudreau, DM; Haneuse, S; Simon, G; Theis, MK; Westbrook, E, 2013) |
| "Citalopram is a selective serotonin reuptake inhibitor with a favorable cardiac-safety profile." | 1.38 | Prolonged QTc interval and torsades de pointes induced by citalopram. ( Abuissa, H; Airey, K; Alla, V; Deshmukh, A; Ulveling, K, 2012) |
| "Mirtazapine is a widely used antidepressant and the aim of this study was to further investigate its antidepressant activity in rats." | 1.33 | Study of mirtazapine antidepressant effects in rats. ( Cassanelli, A; Gambarana, C; Raone, A; Rauggi, R; Tagliamonte, A, 2005) |
| "Depression is a common problem in elderly patients and frequently is treated with antidepressants." | 1.33 | Recurrent hyponatremia associated with citalopram and mirtazapine. ( Akcay, A; Bavbek, N; Kargili, A; Kaya, A, 2006) |
| "Depression is characterized by a lack of "motivation" rather than a lack of "physical space" to move around." | 1.32 | Open space swimming test to index antidepressant activity. ( Alkon, DL; Sun, MK, 2003) |
| "Taurine has been known to be related to certain modifications of the immune system." | 1.32 | Taurine concentration in human blood peripheral lymphocytes: major depression and treatment with the antidepressant mirtazapine. ( Baccichet, E; Carreira, I; Lima, L; Obregón, F; Peña, S; Urbina, M, 2003) |
| "Mirtazapine is a new antidepressant with a tetracyclic chemical structure that is not related to selective serotonin reuptake inhibitors, tricyclic antidepressants, or monoamine oxidase inhibitors." | 1.31 | Hypertensive urgency induced by an interaction of mirtazapine and clonidine. ( Abo-Zena, RA; Bobek, MB; Dweik, RA, 2000) |
| " Long-term administration with imipramine or mirtazapine (10 mg/kg, i." | 1.31 | Chronic treatment with imipramine or mirtazapine antagonizes stress- and FG7142-induced increase in cortical norepinephrine output in freely moving rats. ( Biggio, G; Dazzi, L; Ladu, S; Pira, L; Rivano, A; Spiga, F; Vacca, G, 2002) |
| "Thioridazine (40 mg/day) was coadministered for 1 week, and blood samplings were performed before and after thioridazine coadministration, 12 h after bedtime dosing." | 1.30 | Effects of thioridazine, an inhibitor of CYP2D6, on the steady-state plasma concentrations of the enantiomers of mianserin and its active metabolite, desmethylmianserin, in depressed Japanese patients. ( Kaneko, S; Mihara, K; Otani, K; Suzuki, A; Svensson, JO; Tybring, G; Yasui, N, 1997) |
| "The relationships between the plasma concentrations of mianserin and desmethylmianserin at 18 h after initial dosing and those at steady state were studied in 19 depressed patients receiving 30 mg of mianserin at bedtime." | 1.29 | Prediction of plasma concentrations of mianserin and desmethylmianserin at steady state from those after an initial dose of mianserin. ( Fukushima, Y; Kaneko, S; Mihara, K; Okada, M; Otani, K; Tanaka, O, 1993) |
| "Citalopram was inactive when given alone but it potentiated the antidepressant-like effect of MK-801." | 1.28 | Effects of MK-801 and antidepressant drugs in the forced swimming test in rats. ( Maj, J; Rogóz, Z; Skuza, G; Sowińska, H, 1992) |
| "Depression is the most common psychiatric condition encountered in elderly people." | 1.28 | [Depression in late life]. ( Aoba, A, 1991) |
| "Of these disorders, depression is the most accessible of these to pharmacological treatment; agitation, however, raises the institutional problem." | 1.28 | Psychiatrists and Alzheimer's disease. ( Cazas, A; Flame, E; Ginestet, D, 1989) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 92 (35.66) | 18.7374 |
| 1990's | 34 (13.18) | 18.2507 |
| 2000's | 69 (26.74) | 29.6817 |
| 2010's | 59 (22.87) | 24.3611 |
| 2020's | 4 (1.55) | 2.80 |
| Authors | Studies |
|---|---|
| Czopek, A | 1 |
| Bucki, A | 1 |
| Kołaczkowski, M | 1 |
| Zagórska, A | 1 |
| Drop, M | 1 |
| Pawłowski, M | 1 |
| Siwek, A | 1 |
| Głuch-Lutwin, M | 1 |
| Pękala, E | 1 |
| Chrzanowska, A | 1 |
| Struga, M | 1 |
| Partyka, A | 1 |
| Wesołowska, A | 1 |
| Sato, A | 1 |
| Yasui-Furukori, N | 1 |
| Oda, Y | 1 |
| Yang, M | 1 |
| Suzuki, Y | 1 |
| Shinozaki, M | 1 |
| Shimizu, T | 1 |
| Shimoda, K | 1 |
| Milosavljević, MN | 1 |
| Janković, SM | 1 |
| Kostić, MJ | 1 |
| Pejčić, AV | 1 |
| Schreiber, S | 2 |
| Keidan, L | 1 |
| Pick, CG | 1 |
| Davies, P | 1 |
| Ijaz, S | 1 |
| Williams, CJ | 1 |
| Kessler, D | 2 |
| Lewis, G | 2 |
| Wiles, N | 2 |
| Chmielarz, P | 1 |
| Kuśmierczyk, J | 1 |
| Rafa-Zabłocka, K | 1 |
| Chorązka, K | 1 |
| Kowalska, M | 1 |
| Satała, G | 1 |
| Nalepa, I | 1 |
| Buschkamp, JA | 1 |
| Frohn, C | 1 |
| Juckel, G | 1 |
| Leucht, S | 1 |
| Fennema, H | 1 |
| Engel, RR | 1 |
| Kaspers-Janssen, M | 1 |
| Szegedi, A | 1 |
| Jha, MK | 1 |
| Wakhlu, S | 1 |
| Dronamraju, N | 1 |
| Minhajuddin, A | 1 |
| Greer, TL | 1 |
| Trivedi, MH | 1 |
| Shaheen, AA | 1 |
| Kaplan, GG | 1 |
| Almishri, W | 1 |
| Vallerand, I | 1 |
| Frolkis, AD | 1 |
| Patten, S | 1 |
| Swain, MG | 1 |
| Papazisis, G | 1 |
| Siafis, S | 1 |
| Tzachanis, D | 1 |
| Boudreau, DM | 1 |
| Arterburn, D | 1 |
| Bogart, A | 1 |
| Haneuse, S | 1 |
| Theis, MK | 1 |
| Westbrook, E | 1 |
| Simon, G | 1 |
| Rogóż, Z | 2 |
| Kabziński, M | 1 |
| Sadaj, W | 1 |
| Rachwalska, P | 1 |
| Gądek-Michalska, A | 1 |
| Banerjee, S | 2 |
| Hellier, J | 2 |
| Romeo, R | 2 |
| Dewey, M | 2 |
| Knapp, M | 2 |
| Ballard, C | 2 |
| Baldwin, R | 2 |
| Bentham, P | 2 |
| Fox, C | 2 |
| Holmes, C | 2 |
| Katona, C | 2 |
| Lawton, C | 2 |
| Lindesay, J | 2 |
| Livingston, G | 2 |
| McCrae, N | 2 |
| Moniz-Cook, E | 2 |
| Murray, J | 2 |
| Nurock, S | 2 |
| Orrell, M | 1 |
| O'Brien, J | 2 |
| Poppe, M | 2 |
| Thomas, A | 3 |
| Walwyn, R | 2 |
| Wilson, K | 2 |
| Burns, A | 2 |
| Holland, J | 1 |
| Bhogle, M | 1 |
| Kjaersgaard, MI | 1 |
| Parner, ET | 1 |
| Vestergaard, M | 1 |
| Sørensen, MJ | 1 |
| Olsen, J | 1 |
| Christensen, J | 1 |
| Bech, BH | 1 |
| Pedersen, LH | 1 |
| Puzik, A | 1 |
| Möller, J | 1 |
| Meiss, F | 1 |
| Kontny, U | 1 |
| Rössler, J | 1 |
| Bognár, Z | 1 |
| Vonyik, G | 1 |
| Gazdag, G | 1 |
| Sun, LM | 1 |
| Lin, MC | 1 |
| Liang, JA | 1 |
| Chang, YJ | 1 |
| Chang, SN | 1 |
| Sung, FC | 1 |
| Muo, CH | 1 |
| Kao, CH | 1 |
| Purslow, C | 1 |
| Munzer, A | 1 |
| Sack, U | 1 |
| Mergl, R | 1 |
| Schönherr, J | 1 |
| Petersein, C | 1 |
| Bartsch, S | 1 |
| Kirkby, KC | 1 |
| Bauer, K | 1 |
| Himmerich, H | 1 |
| Künzel, H | 1 |
| Paslakis, G | 2 |
| Westphal, S | 1 |
| Hamann, B | 1 |
| Gilles, M | 3 |
| Lederbogen, F | 3 |
| Deuschle, M | 3 |
| Wróbel, A | 1 |
| Serefko, A | 2 |
| Wlaź, P | 2 |
| Poleszak, E | 2 |
| Kieler, H | 1 |
| Malm, H | 1 |
| Artama, M | 1 |
| Engeland, A | 1 |
| Furu, K | 1 |
| Gissler, M | 1 |
| Nørgaard, M | 1 |
| Stephansson, O | 1 |
| Valdimarsdottir, U | 1 |
| Zoega, H | 1 |
| Haglund, B | 1 |
| Tanidir, C | 1 |
| Tanidir, IC | 1 |
| Tuzcu, V | 1 |
| Verster, JC | 1 |
| van de Loo, AJ | 1 |
| Roth, T | 1 |
| Tripathi, P | 1 |
| Tomar, LR | 1 |
| Goyal, P | 1 |
| Singh, P | 1 |
| Yoshino, Y | 1 |
| Ochi, S | 1 |
| Yamazaki, K | 1 |
| Nakata, S | 1 |
| Abe, M | 1 |
| Mori, Y | 1 |
| Ueno, S | 1 |
| Matsumoto, H | 1 |
| Ohnishi, M | 1 |
| Takegawa, R | 1 |
| Hirose, T | 1 |
| Hattori, Y | 1 |
| Shimazu, T | 1 |
| Grover, S | 1 |
| Avasthi, A | 1 |
| Tripathi, A | 1 |
| Tanra, AJ | 1 |
| Chee, KY | 1 |
| He, YL | 1 |
| Chiu, HF | 1 |
| Kuga, H | 1 |
| Lee, MS | 1 |
| Chong, MY | 1 |
| Udormatn, P | 1 |
| Kanba, S | 1 |
| Yang, SY | 1 |
| Si, TM | 1 |
| Sim, K | 1 |
| Tan, CH | 1 |
| Shen, WW | 1 |
| Xiang, YT | 1 |
| Sartorius, N | 1 |
| Shinfuku, N | 1 |
| Komulainen, E | 1 |
| Heikkilä, R | 1 |
| Meskanen, K | 1 |
| Raij, TT | 1 |
| Nummenmaa, L | 1 |
| Lahti, J | 1 |
| Jylhä, P | 1 |
| Melartin, T | 1 |
| Harmer, CJ | 1 |
| Isometsä, E | 1 |
| Ekelund, J | 1 |
| Duncan, NA | 1 |
| Clifford, KM | 1 |
| Shvarts, OM | 1 |
| Tallon, D | 1 |
| Campbell, J | 1 |
| Chew-Graham, C | 1 |
| Dickens, C | 1 |
| Macleod, U | 1 |
| Peters, TJ | 1 |
| Anderson, IM | 1 |
| Gilbody, S | 1 |
| Hollingworth, W | 1 |
| Davies, S | 1 |
| Gupta, R | 3 |
| Gupta, K | 1 |
| Tripathi, AK | 1 |
| Bhatia, MS | 1 |
| Gupta, LK | 1 |
| Arora, S | 1 |
| Vohora, D | 1 |
| Huang, WL | 1 |
| Liao, SC | 1 |
| Kuo, TB | 1 |
| Chang, LR | 1 |
| Chen, TT | 1 |
| Chen, IM | 1 |
| Yang, CC | 1 |
| Thorkelson, G | 1 |
| Bielefeldt, K | 1 |
| Szigethy, E | 1 |
| Miki, K | 1 |
| Murakami, M | 1 |
| Oka, H | 1 |
| Onozawa, K | 1 |
| Yoshida, S | 2 |
| Osada, K | 1 |
| Jiang, SM | 1 |
| Jia, L | 1 |
| Liu, J | 1 |
| Shi, MM | 1 |
| Xu, MZ | 1 |
| Cornelius, JR | 1 |
| Chung, T | 1 |
| Douaihy, AB | 1 |
| Kirisci, L | 1 |
| Glance, J | 1 |
| Kmiec, J | 1 |
| FitzGerald, D | 1 |
| Wesesky, MA | 1 |
| Salloum, I | 1 |
| Stasiuk, W | 1 |
| Szopa, A | 1 |
| Wyska, E | 1 |
| Świąder, K | 1 |
| Koshiishi, T | 1 |
| Okuyama, K | 1 |
| Fusar-Poli, P | 1 |
| Martinelli, V | 1 |
| Politi, P | 1 |
| Hobson, R | 1 |
| Zimmermann-Viehoff, F | 1 |
| Bergander, B | 1 |
| Meissner, K | 1 |
| Deter, HC | 1 |
| Cheah, CY | 1 |
| Ladhams, B | 1 |
| Fegan, PG | 1 |
| Kim, SW | 1 |
| Shin, IS | 1 |
| Kim, JM | 1 |
| Park, KH | 1 |
| Youn, T | 1 |
| Yoon, JS | 1 |
| Famularo, G | 1 |
| Gasbarrone, L | 1 |
| De Virgilio, A | 1 |
| Minisola, G | 1 |
| Bertram, L | 1 |
| Liss, Y | 1 |
| Grözinger, M | 1 |
| Sarginson, JE | 1 |
| Lazzeroni, LC | 1 |
| Ryan, HS | 1 |
| Schatzberg, AF | 2 |
| Murphy, GM | 2 |
| Belkahia, A | 1 |
| Hillaire-Buys, D | 1 |
| Dereure, O | 1 |
| Guillot, B | 1 |
| Raison-Peyron, N | 1 |
| Rihmer, Z | 1 |
| Purebl, G | 1 |
| Zeman, M | 1 |
| Jirak, R | 1 |
| Jachymova, M | 1 |
| Vecka, M | 1 |
| Tvrzicka, E | 1 |
| Zak, A | 1 |
| Danileviciūte, V | 2 |
| Sveikata, A | 2 |
| Adomaitiene, V | 2 |
| Gumbrevicius, G | 1 |
| Fokas, V | 1 |
| Sveikatiene, R | 1 |
| Luppa, P | 1 |
| Kopf, D | 2 |
| Hamann-Weber, B | 1 |
| Habermeyer, B | 1 |
| Bayer, U | 1 |
| Müller-Spahn, F | 1 |
| Mischo, M | 1 |
| Nigg, C | 1 |
| Kiss, A | 1 |
| Manakova, E | 1 |
| Hubickova, L | 1 |
| Kostalova, J | 1 |
| Zemanova, Z | 1 |
| Tulner, DM | 1 |
| Smith, OR | 1 |
| Schins, A | 1 |
| de Jonge, P | 1 |
| Quere, M | 1 |
| Delanghe, JR | 1 |
| Crijns, HJ | 1 |
| den Boer, JA | 1 |
| Korf, J | 1 |
| Honig, A | 1 |
| Terevnikov, V | 1 |
| Stenberg, JH | 1 |
| Tiihonen, J | 1 |
| Joffe, M | 1 |
| Burkin, M | 1 |
| Tchoukhine, E | 1 |
| Joffe, G | 1 |
| Morita, M | 1 |
| Nakayama, K | 1 |
| Hannon, B | 1 |
| Fitzgerald, P | 1 |
| Murphy, M | 1 |
| Wichniak, A | 2 |
| Wierzbicka, A | 1 |
| Linden, M | 1 |
| Westram, A | 1 |
| Watanabe, N | 1 |
| Omori, IM | 1 |
| Nakagawa, A | 1 |
| Cipriani, A | 1 |
| Barbui, C | 1 |
| Churchill, R | 1 |
| Furukawa, TA | 1 |
| Clark, MS | 1 |
| Smith, PO | 1 |
| Jamieson, B | 1 |
| Mogi, T | 1 |
| Yoshino, A | 1 |
| Ikemoto, G | 1 |
| Nomura, S | 1 |
| Deshmukh, A | 1 |
| Ulveling, K | 1 |
| Alla, V | 1 |
| Abuissa, H | 1 |
| Airey, K | 1 |
| Masana, M | 1 |
| Castañé, A | 1 |
| Santana, N | 1 |
| Bortolozzi, A | 1 |
| Artigas, F | 1 |
| McGuinness, J | 1 |
| Delicata, M | 1 |
| Knud Larsen, J | 1 |
| Schilling, C | 1 |
| Blum, WF | 1 |
| Daseking, E | 1 |
| Colla, M | 1 |
| Weber-Hamann, B | 1 |
| Krumm, B | 1 |
| Heuser, I | 1 |
| Wudy, SA | 1 |
| Uguz, F | 1 |
| Goldberg, RJ | 1 |
| Ahmed, A | 1 |
| Baumann, P | 1 |
| Zullino, DF | 1 |
| Eap, CB | 1 |
| Kesim, M | 1 |
| Yaris, F | 1 |
| Kadioglu, M | 1 |
| Yaris, E | 1 |
| Kalyoncu, NI | 1 |
| Ulku, C | 1 |
| Rénéric, JP | 2 |
| Bouvard, M | 2 |
| Stinus, L | 2 |
| Mavanji, V | 1 |
| Meti, B | 1 |
| Datta, S | 1 |
| Palomäki, H | 3 |
| Berg, A | 3 |
| Meririnne, E | 1 |
| Kaste, M | 3 |
| Lönnqvist, R | 2 |
| Lehtihalmes, M | 3 |
| Lönnqvist, J | 3 |
| Onofrj, M | 1 |
| Luciano, AL | 1 |
| Iacono, D | 1 |
| D'Andreamatteo, G | 1 |
| Teive, HA | 1 |
| de Quadros, A | 1 |
| Barros, FC | 1 |
| Werneck, LC | 1 |
| Van Gool, AR | 1 |
| Bannink, M | 1 |
| Stronks, DL | 1 |
| Vos, MS | 1 |
| Lankisch, PG | 1 |
| Werner, HM | 1 |
| Bonelli, RM | 1 |
| Sun, MK | 1 |
| Alkon, DL | 1 |
| Lima, L | 1 |
| Obregón, F | 1 |
| Urbina, M | 1 |
| Carreira, I | 1 |
| Baccichet, E | 1 |
| Peña, S | 1 |
| Kremer, C | 1 |
| Rodrigues, H | 1 |
| Roose, SP | 1 |
| Pinder, RM | 2 |
| Roxanas, MG | 1 |
| Hidalgo Urbano, RJ | 1 |
| Díaz Infante, E | 1 |
| Recio Mayoral, A | 1 |
| López Rincón, F | 1 |
| Gutiérrez de la Peña, J | 1 |
| Cruz Fernández, JM | 1 |
| Gillman, PK | 1 |
| Norman, TR | 3 |
| Olver, JS | 1 |
| Samborski, W | 1 |
| Lezanska-Szpera, M | 1 |
| Rybakowski, JK | 1 |
| Rauggi, R | 1 |
| Cassanelli, A | 1 |
| Raone, A | 1 |
| Tagliamonte, A | 1 |
| Gambarana, C | 1 |
| Kuliwaba, A | 1 |
| Freeman, WD | 1 |
| Chabolla, DR | 1 |
| Schmid, DA | 1 |
| Uhr, M | 1 |
| Ising, M | 1 |
| Brunner, H | 1 |
| Held, K | 1 |
| Weikel, JC | 1 |
| Sonntag, A | 1 |
| Steiger, A | 1 |
| Wålinder, J | 1 |
| Prochazka, J | 1 |
| Odén, A | 1 |
| Sjödin, I | 1 |
| Dahl, ML | 1 |
| Ahlner, J | 1 |
| Bengtsson, F | 1 |
| Freynhagen, R | 1 |
| Muth-Selbach, U | 1 |
| Lipfert, P | 1 |
| Stevens, MF | 1 |
| Zacharowski, K | 1 |
| Tölle, TR | 1 |
| von Giesen, HJ | 1 |
| Sauvageau, A | 1 |
| Steinmann, C | 1 |
| Bavbek, N | 1 |
| Kargili, A | 1 |
| Akcay, A | 1 |
| Kaya, A | 1 |
| Maciulaitis, R | 1 |
| Kadusevicius, E | 1 |
| Volbekas, V | 1 |
| Koethe, D | 1 |
| Dietl, T | 1 |
| Leweke, FM | 1 |
| Friess, E | 1 |
| Schüle, C | 1 |
| Baghai, TC | 1 |
| di Michele, F | 1 |
| Eser, D | 1 |
| Pasini, A | 1 |
| Schwarz, M | 1 |
| Rupprecht, R | 1 |
| Romeo, E | 1 |
| Raji, MA | 2 |
| Barnum, PD | 1 |
| Freeman, J | 1 |
| Markowitz, AB | 1 |
| Kopecek, M | 1 |
| Sos, P | 1 |
| Brunovsky, M | 1 |
| Bares, M | 1 |
| Stopkova, P | 1 |
| Krajca, V | 1 |
| Shchukina, EP | 1 |
| Kinkul'kina, MA | 1 |
| Borkowska, A | 1 |
| Drozdz, W | 1 |
| Ziółkowska-Kochan, M | 1 |
| Rybakowski, J | 1 |
| Harris, B | 1 |
| Harper, M | 1 |
| Nawishy, S | 1 |
| Hathway, N | 1 |
| Turner, P | 3 |
| Burchinskiĭ, SG | 1 |
| de la Fuente, JR | 1 |
| Berlanga, C | 1 |
| Leonard, BE | 3 |
| Drago, F | 1 |
| Wiegant, VM | 1 |
| Sapienza, G | 1 |
| Aguglia, E | 1 |
| Rapisarda, V | 1 |
| Scapagnini, U | 1 |
| Anthony, M | 1 |
| Mashford, ML | 1 |
| Montgomery, SA | 2 |
| Peutillot, JF | 1 |
| Peutillot, A | 1 |
| Goldstraw, PW | 1 |
| Hanna, N | 1 |
| Moyes, HC | 1 |
| Hingtgen, JN | 2 |
| Hendrie, HC | 1 |
| Aprison, MH | 2 |
| Hoc, J | 1 |
| Nagayama, H | 2 |
| Levin, A | 1 |
| Richards, HH | 1 |
| Midha, RN | 1 |
| Miller, S | 1 |
| Branconnier, RJ | 1 |
| Cole, JO | 1 |
| Ghazvinian, S | 1 |
| Lewis, J | 1 |
| Cairncross, KD | 1 |
| Wilson, WH | 1 |
| Petrie, WM | 1 |
| Ban, TA | 1 |
| Williams, W | 1 |
| Mehta, BM | 1 |
| Spear, FG | 1 |
| Whittington, JR | 1 |
| Hamouz, W | 1 |
| Stulemeijer, SM | 1 |
| Akiyoshi, J | 1 |
| Tsuchiyama, K | 1 |
| Mizobe, Y | 1 |
| Nakamura, M | 1 |
| Kuranaga, H | 1 |
| Mitchell, PB | 1 |
| Mitchell, MS | 1 |
| Manna, V | 2 |
| Bolino, F | 1 |
| Di Cicco, L | 1 |
| Moreau, JL | 1 |
| Bourson, A | 1 |
| Jenck, F | 1 |
| Martin, JR | 1 |
| Mortas, P | 1 |
| Kishimoto, A | 1 |
| Mizukawa, R | 1 |
| Hazama, H | 1 |
| Tanaka, K | 1 |
| Kamase, H | 1 |
| Kunimoto, N | 1 |
| Buist, A | 1 |
| Dennerstein, L | 1 |
| Otani, K | 6 |
| Sasa, H | 1 |
| Kaneko, S | 6 |
| Kondo, T | 1 |
| Fukushima, Y | 4 |
| Mihara, K | 4 |
| Okada, M | 1 |
| Tanaka, O | 1 |
| Tybring, G | 3 |
| Bertilsson, L | 1 |
| Noda, Y | 1 |
| Mamiya, T | 1 |
| Furukawa, H | 1 |
| Nabeshima, T | 1 |
| Yasui, N | 2 |
| Suzuki, A | 1 |
| Svensson, JO | 1 |
| Kasper, S | 1 |
| Praschak-Rieder, N | 1 |
| Tauscher, J | 1 |
| Wolf, R | 1 |
| Ohkubo, T | 1 |
| Nagasaki, T | 1 |
| Sugawara, K | 1 |
| Tabeeva, GR | 1 |
| Levin, IaI | 1 |
| Korotkova, SB | 1 |
| Khanunov, IG | 1 |
| Benazzi, F | 1 |
| De León, OA | 1 |
| Furmaga, KM | 1 |
| Kaltsounis, J | 1 |
| Hares, J | 1 |
| Bruijn, JA | 1 |
| Moleman, P | 1 |
| Mulder, PG | 1 |
| van den Broek, WW | 1 |
| Davis, J | 1 |
| Barkin, RL | 1 |
| Loonen, AJ | 1 |
| Doorschot, CH | 1 |
| Oostelbos, MC | 1 |
| Sitsen, JM | 1 |
| Whale, R | 1 |
| Clifford, EM | 1 |
| Cowen, PJ | 1 |
| Abo-Zena, RA | 1 |
| Bobek, MB | 1 |
| Dweik, RA | 1 |
| Norinder, A | 1 |
| Nordling, S | 1 |
| Häggström, L | 1 |
| García-Campayo, J | 1 |
| Sanz Carrillo, C | 1 |
| Arévalo, E | 1 |
| Claraco, LM | 1 |
| Holm, KJ | 1 |
| Jarvis, B | 1 |
| Foster, RH | 1 |
| Srivastava, SK | 1 |
| Nath, C | 1 |
| Borghi, J | 1 |
| Guest, JF | 1 |
| Waldinger, MD | 1 |
| Berendsen, HH | 1 |
| Schweitzer, DH | 1 |
| Iakovlev, VA | 1 |
| Belinskiĭ, AV | 1 |
| Dorovskikh, IV | 1 |
| Zhbrykunov, VL | 1 |
| Brady, SR | 1 |
| Takamori, K | 1 |
| Okuyama, S | 1 |
| Dazzi, L | 1 |
| Ladu, S | 1 |
| Spiga, F | 1 |
| Vacca, G | 1 |
| Rivano, A | 1 |
| Pira, L | 1 |
| Biggio, G | 1 |
| Joffe, H | 1 |
| Groninger, H | 1 |
| Soares, CN | 1 |
| Nonacs, R | 1 |
| Cohen, LS | 1 |
| Soares, C | 1 |
| Hernández, JL | 1 |
| Ramos, FJ | 1 |
| Infante, J | 1 |
| Rebollo, M | 1 |
| González-Macías, J | 1 |
| Theobald, DE | 1 |
| Kirsh, KL | 1 |
| Holtsclaw, E | 1 |
| Donaghy, K | 1 |
| Passik, SD | 1 |
| Spierings, EL | 1 |
| Lynch, MA | 1 |
| Busch, H | 3 |
| Renfordt, E | 3 |
| Ghose, K | 6 |
| Coppen, A | 6 |
| Hodel, J | 1 |
| Trum, JM | 1 |
| Zapletálek, M | 1 |
| Hanus, H | 1 |
| Kudrnová, K | 1 |
| Swade, C | 1 |
| Wood, K | 1 |
| Burgess, CD | 1 |
| Wadsworth, J | 1 |
| Irwin, P | 1 |
| Fink, M | 2 |
| Russell, GF | 1 |
| Niaz, U | 1 |
| Wakeling, A | 1 |
| Slade, PD | 1 |
| Montgomery, S | 4 |
| McAuley, R | 1 |
| Montgomery, DB | 2 |
| Cronholm, B | 1 |
| Asberg, M | 2 |
| Murphy, JE | 3 |
| Pichot, P | 1 |
| Dreyfus, JF | 1 |
| Pull, C | 1 |
| Bennie, EH | 1 |
| Bridgman, KM | 1 |
| Rao, R | 1 |
| Bailey, J | 3 |
| Peet, M | 2 |
| Brogden, RN | 1 |
| Heel, RC | 1 |
| Speight, TM | 1 |
| Avery, GS | 1 |
| Jaskari, MO | 3 |
| Ahfors, UG | 1 |
| Ginman, L | 2 |
| Lydekcne, K | 1 |
| Tienari, P | 3 |
| Burns, B | 2 |
| de Ridder, JJ | 3 |
| Magnus, RV | 1 |
| Saldaña-Hernández, OH | 1 |
| Oliva-Ruiz, H | 1 |
| Arriaga-Gracia, JJ | 1 |
| Daly, RJ | 1 |
| Browne, PJ | 1 |
| Morgan, E | 1 |
| Svestka, J | 1 |
| Náhunek, K | 1 |
| Cesková, E | 1 |
| Rysánek, R | 1 |
| Gonçalves, N | 1 |
| Wegener, G | 1 |
| McHarg, AM | 1 |
| McHarg, JF | 1 |
| Schmid, E | 1 |
| Ulrich, G | 2 |
| Harms, K | 2 |
| Ahlfors, UG | 1 |
| Lydecken, K | 1 |
| Zis, AP | 1 |
| Goodwin, FK | 1 |
| Burrows, GD | 1 |
| Davies, B | 1 |
| Hamer, A | 1 |
| Vohra, J | 1 |
| Porsolt, RD | 1 |
| Le Pichon, M | 1 |
| Jalfre, M | 1 |
| Kopera, H | 1 |
| Okamoto, K | 1 |
| Nakano, T | 1 |
| Inanaga, K | 1 |
| Bonacek, N | 1 |
| Mihovilović, M | 4 |
| Papić, D | 1 |
| Ivancić-Ljustina, N | 1 |
| Sucić, M | 1 |
| Vogel, HP | 2 |
| Bente, D | 2 |
| Feder, J | 2 |
| Helmchen, H | 2 |
| Müller-Oerlinghausen, B | 2 |
| Bohacek, N | 3 |
| Brändle, A | 1 |
| Fleischhauer, J | 3 |
| Walcher, W | 2 |
| Brändli, A | 1 |
| Donald, JF | 1 |
| Molla, AL | 1 |
| Wheatley, D | 2 |
| Koppens, PC | 1 |
| van Hal, HJ | 1 |
| Bakran, I | 1 |
| Koponen, H | 1 |
| Honkonen, S | 1 |
| Partanen, J | 1 |
| Riekkinen, PJ | 1 |
| Shalev, A | 1 |
| Maj, J | 1 |
| Skuza, G | 1 |
| Sowińska, H | 1 |
| Haupt, M | 1 |
| Hand, TH | 1 |
| Marek, GJ | 1 |
| Seiden, LS | 1 |
| Moon, CA | 2 |
| Jesinger, DK | 1 |
| Valentino, RJ | 1 |
| Curtis, AL | 1 |
| Aoba, A | 1 |
| Ostensen, M | 1 |
| Myhr, K | 1 |
| Wainstein, M | 1 |
| Tannhauser, M | 1 |
| Barros, HM | 1 |
| Tapie, M | 1 |
| Garnier, JP | 1 |
| Tremine, T | 1 |
| Bousquet, B | 1 |
| Manet, L | 1 |
| Dreux, C | 1 |
| Lauzel, JP | 1 |
| Tasaki, H | 1 |
| Florkowski, A | 1 |
| Kocur, J | 1 |
| Rydzyński, Z | 1 |
| Cazas, A | 1 |
| Flame, E | 1 |
| Ginestet, D | 1 |
| Dunbar, GC | 1 |
| Naarala, M | 1 |
| Hiltunen, H | 1 |
| Blacker, R | 1 |
| Shanks, NJ | 1 |
| Chapman, N | 1 |
| Davey, A | 2 |
| Bucknall, C | 1 |
| Brooks, D | 1 |
| Curry, PV | 1 |
| Bridges, PK | 1 |
| Bouras, N | 1 |
| Ankier, SI | 1 |
| Majid, I | 1 |
| Yokoyama, T | 1 |
| Kuroda, K | 1 |
| Uemoto, M | 1 |
| Masui, M | 1 |
| Ide, H | 1 |
| Mita, T | 1 |
| Magni, G | 1 |
| Drijkoningen, GJ | 1 |
| Cliff, G | 1 |
| Martucci, N | 1 |
| Agnoli, A | 1 |
| Maguire, P | 1 |
| Hopwood, P | 1 |
| Tarrier, N | 1 |
| Howell, T | 1 |
| Costa, D | 1 |
| Mogos, I | 1 |
| Toma, T | 1 |
| Morgan, CA | 1 |
| Donaldson, MD | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effect of Mirtazapine Versus Placebo on Appetite, Nutritional Status and Quality of Life in Non-small Cell Lung cáncer Patients With Anorexia; Randomized Double-blind Clinical Trial.[NCT04748523] | 86 participants (Actual) | Interventional | 2018-08-29 | Completed | |||
| Double-blind Pilot Trial of Mirtazapine for the Treatment of Co-occurring AD/MDD.[NCT02185131] | Phase 2 | 16 participants (Actual) | Interventional | 2013-09-30 | Completed | ||
| Treatment of Young Adults With Comorbid AUD/MDD: A Pilot Medication Trial[NCT02646449] | Phase 2 | 11 participants (Actual) | Interventional | 2015-06-30 | Completed | ||
| Hypothalamus-pituitary-adrenal System: Role of the Mineralocorticoid Receptor and Longitudinal Study in Depressed Patients[NCT01049347] | Phase 3 | 127 participants (Actual) | Interventional | 1997-10-31 | Completed | ||
| A Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Agomelatine in the Prevention of Poststroke Depression[NCT05426304] | Phase 4 | 420 participants (Anticipated) | Interventional | 2022-10-01 | Not yet recruiting | ||
| Efficacy and Safety Analyses of Mirtazapine in the Treatment of Malignant Tumor Related Depression: A Phase II, Placebo-controlled, Randomized, Double-blinded Clinical Trial in Advanced Non-small Cell Lung Cancer Patients[NCT02650544] | Phase 2 | 236 participants (Anticipated) | Interventional | 2015-12-31 | Active, not recruiting | ||
| Randomized, Double-blind Clinical Trial of the Use of Mirtazapine Versus Megestrol for the Control of Anorexia-cachexia in Cancer Patients in Palliative Care.[NCT03283488] | Phase 2 | 52 participants (Actual) | Interventional | 2019-03-26 | Completed | ||
| Controlled Trial of Deep Brain Stimulation for Obsessive-Compulsive Disorder[NCT00640133] | Phase 4 | 27 participants (Actual) | Interventional | 2008-03-31 | Active, not recruiting | ||
| Multi-site Confirmatory Efficacy Treatment Trial of Combat-related PTSD[NCT03932773] | Phase 2 | 330 participants (Anticipated) | Interventional | 2019-05-01 | Recruiting | ||
| Randomised Controlled Trial of Neurostimulation for Symptoms of Anorexia Nervosa[NCT05788042] | 70 participants (Anticipated) | Interventional | 2023-08-02 | Recruiting | |||
| A Multisite, Assessor-blinded, Randomized Controlled Trial of Acupuncture for Post-stroke Depression[NCT02644161] | 91 participants (Actual) | Interventional | 2015-10-31 | Completed | |||
| Understanding the Neurocognitive Effects of Fecal Microbiota Transplantation in Major Depressive Disorder Patients With and Without Irritable Bowel Syndrome[NCT05174273] | Phase 2/Phase 3 | 180 participants (Anticipated) | Interventional | 2022-04-06 | Recruiting | ||
| The Safety and Effectiveness of Probiotic Supplementation on Bipolar Depression: a Proof of Concept Randomized Controlled Trial[NCT02155972] | Phase 2 | 16 participants (Actual) | Interventional | 2013-05-31 | Terminated (stopped due to The trial was terminated because of inability to recruit the needed number of participants) | ||
| A Single Ketamine Infusion Combined With Music for Suicidal Ideation During a Depressive Episode: A Randomized Open Label Clinical Trial[NCT04658420] | Phase 2 | 200 participants (Anticipated) | Interventional | 2021-07-01 | Not yet recruiting | ||
| Structural Brain Plasticity in Elderly Depressed Patients Following Electroconvulsive Therapy[NCT02667353] | 110 participants (Actual) | Interventional | 2011-06-30 | Completed | |||
| A Double-Blind, Randomized, Placebo-Controlled Trial of Ramelteon for the Treatment of Insomnia and Mood Stability in Patients With Euthymic Bipolar Disorder.[NCT00552760] | Phase 4 | 90 participants (Actual) | Interventional | 2007-11-30 | Completed | ||
| Clinical Validation Study for EDIT-B Test: an Aid for Differential Diagnosis of Bipolar Disorder, Based on RNA Editing Blood Biomarkers[NCT05603819] | 436 participants (Anticipated) | Observational | 2022-06-29 | Recruiting | |||
| The Role of Orexin in Human Panic Disorder[NCT02593682] | Phase 4 | 3 participants (Actual) | Interventional | 2016-05-31 | Completed | ||
| Physical Fitness and Brain - Interventional Study of the Importance of Physical Fitness on Symptoms of Anxiety, Cognitive Ability and Sick Leave, in Primary Care.[NCT03247270] | 168 participants (Actual) | Interventional | 2017-08-21 | Completed | |||
| Novel Neural Circuit Biomarkers of Major Depression Response to Computer-augmented CBT[NCT03096886] | 90 participants (Anticipated) | Interventional | 2017-06-05 | Active, not recruiting | |||
| A Randomized Controlled Trial of the Safety and Efficacy of Fecal Microbiota Transplantation in a Population With Bipolar Disorder[NCT03279224] | Phase 2/Phase 3 | 35 participants (Actual) | Interventional | 2018-01-01 | Active, not recruiting | ||
| Pre-treatment Biomarker for Clinical Response to Neuronavigation Repetitive Transcranial Magnetic Stimulation (rTMS) in the Acute Phase Treatment of Refractory Major Depressive Episode- Role of Intrinsic Functional Connectivity[NCT03348761] | 128 participants (Anticipated) | Interventional | 2015-08-04 | Recruiting | |||
| Imaging Framework for Testing GABAergic/Glutamatergic Drugs in Bipolar Alcoholics[NCT03220776] | Phase 2 | 54 participants (Actual) | Interventional | 2017-08-07 | Completed | ||
| Study of Antidepressants in Parkinson's Disease[NCT00086190] | Phase 3 | 115 participants (Actual) | Interventional | 2005-06-30 | Completed | ||
| Targeted Alterations in n-3 and n-6 Fatty Acids for the Management of Mood Variability in the Maintenance Phase of Bipolar Disorder[NCT02272010] | 83 participants (Actual) | Interventional | 2014-10-31 | Completed | |||
| ED Treatment of Suicidal Patients With Ketamine Infusion[NCT03502551] | Phase 2 | 0 participants (Actual) | Interventional | 2019-04-01 | Withdrawn (stopped due to Trial never received funding.) | ||
| Prediction of the Therapeutic Response in Depression Based on an Early Neuro-computational Modeling Assessment of Motivation[NCT05866575] | 136 participants (Anticipated) | Interventional | 2023-06-01 | Not yet recruiting | |||
| A Safe Ketamine-Based Therapy for Treatment Resistant Depression[NCT01179009] | 20 participants (Actual) | Interventional | 2012-04-30 | Completed | |||
| Double-Blind, Placebo-Controlled Trial of Ketamine Therapy in Treatment-Resistant Depression (TRD)[NCT01920555] | Phase 2 | 99 participants (Actual) | Interventional | 2014-12-31 | Completed | ||
| The Impact of Spiritual Healing on Moderate Depression in Adults: A Pilot Randomized Controlled Trial (RCT)[NCT04766242] | 28 participants (Anticipated) | Interventional | 2021-03-01 | Not yet recruiting | |||
| Double-blind Trial of Intraoperative Ketamine Versus Saline in Depressed Patients Undergoing Anesthesia for Non-cardiac Surgery[NCT03861988] | Phase 4 | 45 participants (Actual) | Interventional | 2019-08-22 | Completed | ||
| Analisi Dei Marcatori di Stress Ossidativo in Pazienti Affetti da Tumore Della Mammella, Sottoposte a Radioterapia Postoperatoria e Psicoterapia Con Elementi di Musicoterapia[NCT04446624] | 60 participants (Actual) | Interventional | 2018-02-01 | Completed | |||
| [NCT05753943] | 0 participants | Expanded Access | No longer available | ||||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Level of drinking, as indicated by the number of drinks per day as recorded on the Timeline Follow-Back calendar. (NCT02185131)
Timeframe: 12 Weeks
| Intervention | Drinks per drinking day (Mean) |
|---|---|
| Mirtazapine | 3.5 |
| Placebo | 4.4 |
Level of depressive symptoms, as indicated by the score on the Beck Depression Inventory. The Beck Depression Inventory II scoring range is as follows: 0-13 minimal depressive symptoms, 14-19 mild depressive symptoms, 20-28 moderate depressive symptoms and 29-63 severe depressive symptoms. (NCT02185131)
Timeframe: 12 Weeks
| Intervention | Units on a scale (Mean) |
|---|---|
| Mirtazapine | 27.6 |
| Placebo | 26.1 |
Level of drinking, as indicated by the number of drinks per day as recorded on the Timeline Follow-Back calendar. (NCT02646449)
Timeframe: 12 Weeks
| Intervention | Drinks per drinking day (Mean) |
|---|---|
| Mirtazapine | 2.8 |
| Placebo | 2.0 |
Level of depressive symptoms, as indicated by the score on the Beck Depression Inventory. The Beck Depression Inventory II scoring range is as follows: 0-13 minimal depressive symptoms, 14-19 mild depressive symptoms, 20-28 moderate depressive symptoms and 29-63 severe depressive symptoms. (NCT02646449)
Timeframe: 12 Weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Mirtazapine | 8.0 |
| Placebo | 3.3 |
The Behavioral Activation for Depression Scale (BADS) is a 29-item scale that measures the role of aversive controlling stimuli and escape and avoidance behavior in depression, specifically when and how participants become more activated over the course of treatment. Total scores range from 29-203 and lower scores indicate higher levels of escape and avoidance behavior from depression in the past week. (NCT00640133)
Timeframe: Total BADS score observed means at month-12 time point.
| Intervention | units on a scale (Mean) |
|---|---|
| Active DBS | 85.3 |
| Sham DBS | 80.3 |
A numeric scale (0 through 100) used to rate the social, occupational, and psychological overall functioning during the week of poorest functioning in the past month. Higher scores indicate a higher level of functioning, while low scores indicate impaired global functioning. (NCT00640133)
Timeframe: GAF score observed means at month-12
| Intervention | units on a scale (Mean) |
|---|---|
| Active DBS | 54.8 |
| Sham DBS | 53.7 |
Hamilton Anxiety Rating Scale (HARS) is a 14-item test measuring the severity of anxiety symptoms. It provides measures of overall anxiety, psychic anxiety (mental agitation and psychological distress), and somatic anxiety (physical complaints related to anxiety); total scores range from 0-56. Higher scores indicate higher levels of anxiety over the past week. (NCT00640133)
Timeframe: HARS total score observed means at month-12 time point.
| Intervention | units on a scale (Mean) |
|---|---|
| Active DBS | 12.6 |
| Sham DBS | 15.7 |
The Hamilton Depression Rating Scale (HDRS) measures the severity of depressive symptoms in adults. The evaluator-administered ratings measure depressed mood, guilt, suicide, insomnia, work/activities, retardation, agitation, psychic and somatic anxiety, genital symptoms, hypochondriasis, and insight during the past week. Total scores range from 0-72 and higher scores indicate the presence of more severe depression over the past week. Note: this measure was only administered at baseline and month-3. (NCT00640133)
Timeframe: Total HDRS score observed means at month-3 time point.
| Intervention | units on a scale (Mean) |
|---|---|
| Active DBS | 16.8 |
| Sham DBS | 19.4 |
"The Montgomery Asberg Depression Rating Scale (MADRS) is an interviewer-administered measure assessing the ten symptoms of depression most sensitive to change. Apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts are assessed and total scores range from 0-60 with higher scores representing the presence of more severe depression over the past week.~interviewer-administered measure assessing" (NCT00640133)
Timeframe: MADRS total score observed means at month-12 time point.
| Intervention | units on a scale (Mean) |
|---|---|
| Active DBS | 17.1 |
| Sham DBS | 18.5 |
The Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q) is a self-administered measure to assess the degree of enjoyment and satisfaction experienced by participants in various areas of daily functioning. We used the 16-item short form with total scores ranging from 16-80. Higher scores indicate greater satisfaction experienced during the past week. (NCT00640133)
Timeframe: QLESQ total score observed means at month-12 time point.
| Intervention | units on a scale (Mean) |
|---|---|
| Active DBS | 39.8 |
| Sham DBS | 42.7 |
A numeric scale (0 through 100) used to rate the social, occupational, and psychological functioning during the week of poorest functioning in the past month. Higher scores indicate higher levels of social and occupational functioning, while low scores represent social and occupational impairment. (NCT00640133)
Timeframe: SOFAS score observed means at month-12 time point.
| Intervention | units on a scale (Mean) |
|---|---|
| Active DBS | 55.9 |
| Sham DBS | 53.9 |
The Yale-Brown Obsessive-Compulsive Scale (YBOCS) is a 10 question evaluator-administered measure assessing the severity of obsessions and compulsions over the past week. Obsession and compulsion severity are evaluated separately (ratings from 0-20 for each category) with total scores ranging from 0-40. Higher scores for obsessions, compulsions and total score indicate more severe symptoms over the past week. (NCT00640133)
Timeframe: YBOCS total score observed means at month-12
| Intervention | units on a scale (Mean) |
|---|---|
| Active DBS | 20.5 |
| Sham DBS | 20.9 |
3-part (mania, depression, overall bipolar illness), physician-administered scale used to assess global illness severity; used to measure change. Each part is rated from 1-7, higher scores represent more severe mental illness. Only overall bipolar rating was used. (NCT00552760)
Timeframe: Monthly for 6 months
| Intervention | units on scale (Mean) | ||||||
|---|---|---|---|---|---|---|---|
| Baseline | Month 1 | Month 2 | Month 3 | Month 4 | Month 5 | Month 6 | |
| Placebo | 2.15 | 2.25 | 2.90 | 2.93 | 2.98 | 2.99 | 2.41 |
| Ramelteon | 2.14 | 2.29 | 2.24 | 2.53 | 2.36 | 2.46 | 2.54 |
Survival analysis techniques, including Kaplan Meier curves, were used to evaluate group differences in time to relapse. Relapse was defined as a medication initiation or change for manic/depressed/mixed symptoms, a hospitalization for manic/depressed/mixed symptoms, MADRS score >= 16, YMRS score > 14, and suicide risk or imminent risk of suicide. Time to relapse was measured discretely in terms of the number of assessment visits until discontinued from the study. (NCT00552760)
Timeframe: Monthly for 6 months
| Intervention | Cumulative proportion of participants (Number) | ||||||
|---|---|---|---|---|---|---|---|
| Baseline | Month 1 | Month 2 | Month 3 | Month 4 | Month 5 | Month 6 | |
| Placebo | 1.00 | 0.951 | 0.588 | 0.448 | 0.384 | 0.320 | 0.320 |
| Ramelteon | 1.00 | 0.929 | 0.849 | 0.716 | 0.661 | 0.632 | 0.566 |
10-item, standardized, well-validated scale used to measure severity of depressive symptoms; sensitive to treatment effects in depressed outpatients. Scores range from 0-60, higher scores represent more severe depressive symptoms. (NCT00552760)
Timeframe: Monthly for 6 months
| Intervention | units on scale (Mean) | ||||||
|---|---|---|---|---|---|---|---|
| Baseline | Month 1 | Month 2 | Month 3 | Month 4 | Month 5 | Month 6 | |
| Placebo | 8.27 | 8.90 | 11.13 | 11.85 | 13.03 | 11.59 | 10.46 |
| Ramelteon | 7.79 | 8.34 | 7.23 | 9.17 | 8.45 | 8.56 | 10.40 |
Self-rated scale to measure quality of sleep via questions regarding sleep latency, duration, efficiency, disturbances, use of sleep medication, and daytime dysfunction. Scores range from 0-21, higher scores represent more significant sleep disturbance. (NCT00552760)
Timeframe: Monthly for 6 months
| Intervention | units on scale (Mean) | ||||||
|---|---|---|---|---|---|---|---|
| Baseline | Month 1 | Month 2 | Month 3 | Month 4 | Month 5 | Month 6 | |
| Placebo | 10.88 | 9.28 | 9.71 | 10.38 | 9.03 | 8.66 | 8.76 |
| Ramelteon | 10.17 | 8.16 | 7.93 | 7.89 | 7.21 | 6.62 | 6.90 |
11-item standardized, well-validated scale used to measure manic symptoms; sensitive to treatment effects in manic patients. Scores range from 0-60, higher scores represent more severe manic symptoms. (NCT00552760)
Timeframe: Monthly for 6 months
| Intervention | units on scale (Mean) | ||||||
|---|---|---|---|---|---|---|---|
| Baseline | Month 1 | Month 2 | Month 3 | Month 4 | Month 5 | Month 6 | |
| Placebo | 6.59 | 6.46 | 7.75 | 8.09 | 4.95 | 5.71 | 6.72 |
| Ramelteon | 7.02 | 5.89 | 5.91 | 6.60 | 5.93 | 5.18 | 6.51 |
Concentrations of GABA+, referenced to unsuppressed water and corrected for within-voxel CSF proportion, in dorsal anterior cingulate cortex measured via Proton Magnetic Resonance Spectroscopy (i.e., MEGA-PRESS). (NCT03220776)
Timeframe: Day 5 of each experimental condition
| Intervention | mmol/kg (Mean) |
|---|---|
| N-Acetylcysteine | 3.90 |
| Gabapentin | 3.93 |
| Placebo Oral Tablet | 3.73 |
Concentrations of Glx (i.e., glutamate + glutamine), referenced to unsuppressed water and corrected for within-voxel CSF proportion, in dorsal anterior cingulate cortex measured via Proton Magnetic Resonance Spectroscopy. (NCT03220776)
Timeframe: Day 5 of each experimental condition
| Intervention | mmol/kg (Mean) |
|---|---|
| N-Acetylcysteine | 21.59 |
| Gabapentin | 21.69 |
| Placebo Oral Tablet | 22.25 |
Beck Depression Inventory II ranges from 0-63. Higher score indicates more severe depression. 0-13 minimal depression, 14-19 mild depression, 20-28 moderate depression, 29-63 severe depression. (NCT00086190)
Timeframe: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase
| Intervention | Change in BDI-II score (Mean) |
|---|---|
| Paroxetine | -9.7 |
| Venlafaxine Extended Release | -9.6 |
| Placebo | -5.2 |
Brief Psychiatric Rating Scale. Maximum score 126. Higher score indicates greater psychiatric difficulties. (NCT00086190)
Timeframe: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase
| Intervention | Change in BPRS score (Mean) |
|---|---|
| Paroxetine | -9.0 |
| Venlafaxine Extended Release | -9.8 |
| Placebo | -4.4 |
Geriatric Depression Scale ranges from 0-30. Higher score indicates more severe depression. 0-9 normal, 10-19 mild depression, 20-30 severe depression. (NCT00086190)
Timeframe: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase
| Intervention | Change in GDS score (Mean) |
|---|---|
| Paroxetine | -6.9 |
| Venlafaxine Extended Release | -6.9 |
| Placebo | -2.8 |
Change in Hamilton Rating Scale for Depression over 12 weeks. Hamilton Depression Rating Scale ranges from 0-50. Higher scores represent more significant depression. Mild depression ranges from 8-13, moderate depression from 14-18, severe 19-22 and very severe any score over 23. (NCT00086190)
Timeframe: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase
| Intervention | Change in HAM-D score (Mean) |
|---|---|
| Paroxetine | -13.0 |
| Venlafaxine Extended Release | -11.0 |
| Placebo | -6.8 |
Montgomery-Asberg Depression Rating Scale ranges from 0-60. Higher score indicates more severe depression. 0-6 normal, 7-19 mild depression, 20-34 moderate depression, greater than 34 severe depression. (NCT00086190)
Timeframe: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase
| Intervention | Change in MADRS score (Mean) |
|---|---|
| Paroxetine | -13.6 |
| Venlafaxine Extended Release | -10.9 |
| Placebo | -6.6 |
Parkinson's Disease Questionnaire (PDQ-39) - Emotional Well-Being maximum score 24, minimum score of 0.Lower score indicates a better perceived health status. (NCT00086190)
Timeframe: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase
| Intervention | Change in PDQ-39 Emotional score (Mean) |
|---|---|
| Paroxetine | -21.4 |
| Venlafaxine Extended Release | -20.7 |
| Placebo | -10.9 |
Parkinson's Disease Questionnaire (PDQ-39) Total. Range 0-100. Lower score indicates a better perceived health status. (NCT00086190)
Timeframe: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase
| Intervention | Change in PDQ-39 score (Mean) |
|---|---|
| Paroxetine | -8.0 |
| Venlafaxine Extended Release | -8.4 |
| Placebo | -5.3 |
Pittsburgh Sleep Quality Index scores range from 0-21, with higher scores indicating severe sleep difficulties. (NCT00086190)
Timeframe: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase
| Intervention | Change in PQSI score (Mean) |
|---|---|
| Paroxetine | -2.1 |
| Venlafaxine Extended Release | -2.6 |
| Placebo | -1.1 |
Short Form 36 Health Survey. Range 0-100. Higher score indicates a better perceived quality of life. (NCT00086190)
Timeframe: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase
| Intervention | Change in SF-36 mental score (Mean) |
|---|---|
| Paroxetine | 11.4 |
| Venlafaxine Extended Release | 9.5 |
| Placebo | 4.8 |
Short Form 36 Health Survey - Mental Health subscale ranges from 0-100. Higher score indicates a better perceived quality of life. (NCT00086190)
Timeframe: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase
| Intervention | Change in SF-36 Mental Health score (Mean) |
|---|---|
| Paroxetine | 16.7 |
| Venlafaxine Extended Release | 17.4 |
| Placebo | 9.7 |
Short Form 36 Health Survey - Emotional subscale ranges from 0-100. Higher score indicates a better perceived quality of life. (NCT00086190)
Timeframe: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase
| Intervention | Change in SF-36 Role score (Mean) |
|---|---|
| Paroxetine | 39.5 |
| Venlafaxine Extended Release | 26.9 |
| Placebo | 12.7 |
Short Form 36 Health Survey - Vitality subscale ranges from 0-100. Higher score indicates a better perceived quality of life. (NCT00086190)
Timeframe: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase
| Intervention | Change in SF-36 vitality score (Mean) |
|---|---|
| Paroxetine | 13.5 |
| Venlafaxine Extended Release | 9.1 |
| Placebo | 4.7 |
Snaith Clinical Anxiety Scale. Range 0-21. Higher scores indicate increased anxiety. Score greater than 8 indicates clinical anxiety. (NCT00086190)
Timeframe: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase
| Intervention | Change in CAS score (Mean) |
|---|---|
| Paroxetine | -3.6 |
| Venlafaxine Extended Release | -3.2 |
| Placebo | -2.4 |
Unified Parkinson's Disease Rating Scale. Higher score indicates more severe Parkinson's disease symptoms. Total maximum = 176. Mental maximum = 52, Activities of Daily Living maximum = 52, Motor maximum = 72. Minimum = 0. (NCT00086190)
Timeframe: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase
| Intervention | Change in UPDRS score (Mean) |
|---|---|
| Paroxetine | -8.7 |
| Venlafaxine Extended Release | -7.0 |
| Placebo | -4.3 |
Unified Parkinson's Disease Rating Scale - Bulbar maximum score 24, minimum score of 0. Higher score indicates more severe Parkinson's disease symptoms. (NCT00086190)
Timeframe: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase
| Intervention | Change in UPDRS-Bulbar score (Mean) |
|---|---|
| Paroxetine | -1.4 |
| Venlafaxine Extended Release | -1.4 |
| Placebo | -0.5 |
Unified Parkinson's Disease Rating Scale - Motor has a maximum score of 72, minimum score of 0. Higher score indicates more severe Parkinson's disease symptoms. (NCT00086190)
Timeframe: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase
| Intervention | Change in UPDRS-motor score (Mean) |
|---|---|
| Paroxetine | -4.3 |
| Venlafaxine Extended Release | -2.0 |
| Placebo | -1.0 |
Unified Parkinson's Disease Rating Scale - Tremor subscale ranges from 0-23. Higher score indicates more severe Parkinson's disease symptoms. (NCT00086190)
Timeframe: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase
| Intervention | Change in UPDRS-tremor score (Mean) |
|---|---|
| Paroxetine | 0.4 |
| Venlafaxine Extended Release | 0.5 |
| Placebo | -0.6 |
The Montgomery-Asberg Depression Rating Scale (MADRS) is a 10-item scale that measures the severity of depression, with a higher score indicating a higher level of depression. The range of scores is 0 to 60. (NCT01179009)
Timeframe: 8 weeks
| Intervention | Scores on a scale (Mean) |
|---|---|
| Ketamine 100-hour Infusion | -9.0 |
| Ketamine 40-minute Infusion | -6.4 |
"The CGI-I is a clinician rated single-item scale: Compared to the patient's condition at admission, how much has the patient changed?, rated on a 7-point response scale: 1 = Very much improved, 2 = Much improved, 3 = Minimally improved, 4 = No change, 5 = Minimally worse, 6 = Much worse, and 7 = Very much worse. In this case, admission referred to the CGI-S screening assessments performed between Day -28 an -7, one conducted during the screening visit, and a second rating conducted by a remote, independent rater." (NCT01920555)
Timeframe: A baseline assessment was made on Day 0, preceding infusion (i.e., treatment). Outcome assessments were made on days 1, 3, 5, 7, 14, and 30. The primary endpoint for this study was Day 3. Thus, the outcome measure table provides data on Days 0, 1 and 3
| Intervention | units on a scale (Mean) | ||
|---|---|---|---|
| Day 0 | Day 1 | Day 3 | |
| Ketamine 0.1mg | 3.8888889 | 3.0625000 | 2.9333333 |
| Ketamine 0.2mg | 4.0500000 | 3.3684211 | 2.8421053 |
| Ketamine 0.5mg | 4.1363636 | 2.6363636 | 2.5714286 |
| Ketamine 1.0mg | 4.0000000 | 3.0500000 | 2.5500000 |
| Midazolam 0.045mg | 4.1578947 | 3.6111111 | 3.1666667 |
"The CGI-S is a clinician rated single-item scale: How depressed is the patient at this time?, rated on a 7-point response scale: 1 = Normal, not at all depressed, 2 = Borderline depressed, 3 = Mildly depressed, 4 = Moderately depressed. 5 = Markedly depressed, 6 = severely depressed, 7 = Among the most severely depressed patients. When rating patients, clinicians were asked to consider the past 24 hours." (NCT01920555)
Timeframe: A baseline assessment was made on Day 0, preceding infusion (i.e., treatment). Outcome assessments were made on days 1, 3, 5, 7, 14, and 30. The primary endpoint for this study was Day 3. Thus, the outcome measure table provides data on Days 0, 1 and 3
| Intervention | units on a scale (Mean) | ||
|---|---|---|---|
| Day 0 | Day 1 | Day 3 | |
| Ketamine 0.1mg | 5.0000000 | 3.5625000 | 3.4000000 |
| Ketamine 0.2mg | 5.2000000 | 4.2631579 | 3.7368421 |
| Ketamine 0.5mg | 4.8636364 | 3.2727273 | 3.1428571 |
| Ketamine 1.0mg | 5.2000000 | 3.5000000 | 3.3000000 |
| Midazolam 0.045mg | 5.000000 | 4.555556 | 4.1666667 |
"The CPAS is a 16-item self-report scale to assess the level to which participants experience persistent distress due to feeling that they have not returned to their normal or premorbid state. Items (e.g., I look forward to things) are rated on a 5-point scale (0=not at all, 1=very much less than normal, 2=much less than normal, 3=slightly less than normal, 4=same as best or normal self). The possible scale range is 0 to 64, with higher scores indicating greater recovery from depression. Patients were asked to rate their experience of the past 24 hours." (NCT01920555)
Timeframe: A baseline assessment was made on Day 0, preceding infusion (i.e., treatment). Outcome assessments were made on days 1, 3, 5, 7, 14, and 30. The primary endpoint for this study was Day 3. Thus, the outcome measure table provides data on Days 0, 1 and 3
| Intervention | units on a scale (Mean) | ||
|---|---|---|---|
| Day 0 | Day 1 | Day 3 | |
| Ketamine 0.1mg | 19.3333333 | 35.2500000 | 38.8666667 |
| Ketamine 0.2mg | 20.5000000 | 27.0526316 | 28.3888889 |
| Ketamine 0.5mg | 20.6363636 | 40.8696964 | 39.7619048 |
| Ketamine 1.0mg | 21.2500000 | 33.0000000 | 37.4500000 |
| Midazolam 0.045mg | 21.2631579 | 24.4444444 | 33.3750000 |
"The CADSS is a 23-item self-report scale for the assessment of dissociative states. It is a reliable, valid self-report instrument. The severity of each dissociative symptom ranges from 0 (not present) to 4 (extreme). The total score is calculated by summing across items, with a total possible range of 0-92. The CADSS was administered right before infusion, and 40, 80 minute and 120 minutes after the start of infusion. The timeframe is at this moment." (NCT01920555)
Timeframe: Day 0/baseline at 0, 40, 80, and 120 minutes
| Intervention | units on a scale (Mean) | |||
|---|---|---|---|---|
| Minute 0 | Minute 40 | Minute 80 | Minute 120 | |
| Ketamine 0.1mg | 0.1111111 | 3.0000000 | 0.4444444 | 0.0555556 |
| Ketamine 0.2mg | 0.1000000 | 4.0500000 | 0.1000000 | 0 |
| Ketamine 0.5mg | 0 | 14.2727273 | 0.7727273 | 0.1363636 |
| Ketamine 1.0mg | 0.1000000 | 24.6842105 | 1.8000000 | 0.6500000 |
| Midazolam 0.045mg | 0.4210526 | 2.6842105 | 1.1578947 | 0.5789474 |
The HAMD6 is a 6-item clinician-rated scale, where clinicians rate the presence of depression symptoms (i.e., depressed mood, guilt, work and interests, psychomotor retardation, psychic anxiety, somatic symptoms) on a 5-point scale, where 0 = not present, and 1-4 represent increasingly severe symptoms. One item (i.e., somatic symptoms) is rated on only a 3-point scale, ranging from 0-2. The possible scale range is 0-22, where higher values represent more severe depression. This instrument is completed with a structured interview guide by the clinician based on his/her assessment of the patient's symptoms. This structured interview has been validated for use with time frames shorter than one week. In this study, the HAMD6 was used to assess symptoms occurring in the past 24 hours. (NCT01920555)
Timeframe: A baseline assessment was made on Day 0, preceding infusion (i.e., treatment). Outcome assessments were made on days 1, 3, 5, 7, 14, and 30. The primary endpoint for this study was Day 3. Thus, the outcome measure table provides data on Days 0, 1, & 3
| Intervention | units on a scale (Mean) | ||
|---|---|---|---|
| Day 0 | Day 1 | Day 3 | |
| Ketamine 0.1mg | 12.5555556 | 7.5000000 | 6.8000000 |
| Ketamine 0.2mg | 12.7500000 | 9.2631579 | 8.4736842 |
| Ketamine 0.5mg | 12.5909091 | 5.8636364 | 5.9047619 |
| Ketamine 1.0mg | 12.6315789 | 6.9000000 | 7.2000000 |
| Midazolam 0.045mg | 13.0526316 | 10.6666667 | 9.0555556 |
"The MADRS is a 10-item clinician-rated scale measuring depression severity. Symptoms are rated on a 7-point scale, where 0 = not present, and 1-6 represent increasing severity. Values 2, 4, and 6 have specific anchoring text (e.g., 2=Difficulties in starting activities. 4=Difficulties in starting simple routine activities which are carried out with effort, 6=Complete lassitude. Unable to do anything without help.) Values 1, 3, and 5 do not have specific text. The possible scale range is 0-60, where higher values represent higher severity. In this study, the MADRS was used to rate symptoms occurring in the past 3 days." (NCT01920555)
Timeframe: A baseline assessment was made on Day 0, preceding infusion (i.e., treatment). Outcome assessments were made on days 3, 5, 7, 14, and 30. The primary endpoint for this study was Day 3. Thus, the outcome measure table provides data on Days 0 and 3.
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Day 0 | Day 3 | |
| Ketamine 0.1mg | 33.8333333 | 19.6666667 |
| Ketamine 0.2mg | 34.4500000 | 22.6315789 |
| Ketamine 0.5mg | 31.5909091 | 14.7619048 |
| Ketamine 1.0mg | 32.6500000 | 17.1000000 |
| Midazolam 0.045mg | 33.6315789 | 24.8333333 |
The Columbia Suicide Severity Rating Scale (C-SSRS): The C-SSRS is a low-burden measure of the spectrum of suicidal ideation and behavior that was developed in the National Institute of Mental Health Treatment of Adolescent Suicide Attempters Study to assess severity and track suicidal events through any treatment. It is a clinical interview providing a summary of both ideation and behavior that can be administered during any evaluation or risk assessment to identify the level and type of suicidality present. The C-SSRS can also be used during treatment to monitor for clinical worsening or improvement. It contains 5 rating scale questions (yes/no) for suicidal ideation increasing severity and 5 rating scale questions (yes/no) for suicidal behavior of increasing severity. The time frame is for both lifetime and the past six months for the Baseline/Screening scale and since the last visit for the Since Last Visit scale. (NCT01920555)
Timeframe: Screening Visit and Days 0, 1, 3, 5, 7, 14 and 30 combined
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Screening: # with suicidal ideation/behavior | Follow-Up: # with suicidal ideation/behavior | |
| Ketamine 0.1mg | 17 | 15 |
| Ketamine 0.2mg | 15 | 9 |
| Ketamine 0.5mg | 17 | 10 |
| Ketamine 1.0mg | 14 | 6 |
| Midazolam 0.045mg | 17 | 13 |
"CBC~Chemistry (Total bilirubin, AST, ALT, GGT, ALK Phosphatase, Creatinine, BUN/Urea, Glucose, Uric Acid)~Testing was performed by study site laboratories and used institutional normal lab value ranges." (NCT01920555)
Timeframe: Day 3 and Early Termination Visit (approximately 3 weeks following intervention)
| Intervention | Participants (Count of Participants) | ||||
|---|---|---|---|---|---|
| Chemistry ALT(SGPT) | Chemistry AST(SGOT) | Chemistry Total Bilirubin | Chemistry Remaining Tests | CBC | |
| Ketamine 0.1mg | 0 | 0 | 0 | 0 | 0 |
| Ketamine 0.2mg | 1 | 1 | 1 | 0 | 0 |
| Ketamine 0.5mg | 0 | 0 | 0 | 0 | 0 |
| Ketamine 1.0mg | 0 | 0 | 0 | 0 | 0 |
| Midazolam 0.045mg | 0 | 0 | 0 | 0 | 0 |
"The SHAPS is a 14-item self-report scale to measure hedonic tone. Items (e.g., I would enjoy reading a book, magazine, or newspaper.) are rated on a 4-point scale (1=strongly disagree, 2=disagree, 3=agree, 4=strongly agree). Either of the 'disagree' responses scores 1 point, and either of the 'agree' responses scores 0 points, for a total scale range of 0-14. Higher scores indicate greater inability to experience pleasure. Patients were asked to rate their experience of the past 24 hours." (NCT01920555)
Timeframe: A baseline assessment was made on Day 0, preceding infusion (i.e., treatment). Outcome assessments were made on days 1, 3, 5, 7, 14, and 30. The primary endpoint for this study was Day 3. Thus, the outcome measure table provides data on Days 0, 1 and 3
| Intervention | units on a scale (Mean) | ||
|---|---|---|---|
| Day 0 | Day 1 | Day 3 | |
| Ketamine 0.1mg | 7.2222222 | 3.9375000 | 3.5333333 |
| Ketamine 0.2mg | 7.5500000 | 5.7368421 | 6.3888889 |
| Ketamine 0.5mg | 6.5909091 | 2.22727273 | 3.0000000 |
| Ketamine 1.0mg | 7.3500000 | 4.3000000 | 3.6500000 |
| Midazolam 0.045mg | 6.4736842 | 5.0000000 | 4.2500000 |
"The SDQ is a 44-item self-report scale, which aims to measure depression more comprehensively by including the assessment of symptoms in the anxiety-depression spectrum, including symptoms of irritability, anger attacks, and anxiety. Items are rated on an 6-point Likert scale, where participants are asked to rate if a specific symptom (e.g. How has your mood been over the past 24 hours?) is normal for him or her (score = 2), what is better than normal (score = 1), and what is worse than normal (scores = 3-6). The total scale score is calculated by averaging across the items, resulting in a possible range from 1 to 6. Higher scores indicate greater depression severity. When rating, patients were asked to consider their symptoms during the past 24 hours." (NCT01920555)
Timeframe: A baseline assessment was made on Day 0, preceding infusion (i.e., treatment). Outcome assessments were made on days 1, 3, 5, 7, 14, and 30. The primary endpoint for this study was Day 3. Thus, the outcome measure table provides data on Days 0, 1 and 3
| Intervention | units on a scale (Mean) | ||
|---|---|---|---|
| Day 0 | Day 1 | Day 3 | |
| Ketamine 0.1mg | 3.5164141 | 2.5752843 | 2.5106061 |
| Ketamine 0.2mg | 3.4636364 | 2.9096195 | 2.7828283 |
| Ketamine 0.5mg | 3.5392562 | 2.3109504 | 2.5573593 |
| Ketamine 1.0mg | 3.4113636 | 2.6113636 | 2.5909091 |
| Midazolam 0.045mg | 3.4264507 | 2.9200573 | 2.8751353 |
Number of days from admission (day of surgery) through discharge after surgery. (NCT03861988)
Timeframe: Average approximately 3 days post-intervention
| Intervention | days (Mean) |
|---|---|
| Open Label Ketamine | 3.7 |
| Double Blind Ketamine | 1.9 |
| Double Blind Placebo | 4.0 |
Remission defined as a MADRS score of <=12 on day 14. MADRS score range: 0 to 60, a lower score indicates lower severity of symptoms. (NCT03861988)
Timeframe: Post-intervention day 14
| Intervention | Participants (Count of Participants) |
|---|---|
| Open Label Ketamine | 3 |
| Double Blind Ketamine | 8 |
| Double Blind Placebo | 10 |
"Average pain intensity in the past 24 hours, rated on a numerical scale from 0 to 10 (with 0 representing No pain and 10 representing Pain as bad as you can imagine)." (NCT03861988)
Timeframe: Post-intervention days 1, 2, 3, 5, 7 and 14
| Intervention | score on a scale (Mean) | |||||
|---|---|---|---|---|---|---|
| Day 1 | Day 2 | Day 3 | Day 5 | Day 7 | Day 14 | |
| Double Blind Ketamine | 6.0 | 5.3 | 5.5 | 5.5 | 5.1 | 4.8 |
| Double Blind Placebo | 5.2 | 6.0 | 5.2 | 4.4 | 4.4 | 3.7 |
| Open Label Ketamine | 4.6 | 5.5 | 3.5 | 4.4 | 4.8 | 4.4 |
"Pain interference in the past 24 hours, rated on a numerical scale from 0 to 10 (with 0 representing Does not interfere and 10 representing Completely interferes)." (NCT03861988)
Timeframe: Post-intervention days 1, 2, 3, 5, 7 and 14
| Intervention | units on a scale (Mean) | |||||
|---|---|---|---|---|---|---|
| Day 1 | Day 2 | Day 3 | Day 5 | Day 7 | Day 14 | |
| Double Blind Ketamine | 8.1 | 8.0 | 7.5 | 7.0 | 6.7 | 6.2 |
| Double Blind Placebo | 7.6 | 8.1 | 7.7 | 7.0 | 7.2 | 5.7 |
| Open Label Ketamine | 6.0 | 6.3 | 4.8 | 6.6 | 7.6 | 4.8 |
This outcome measures how many cumulative morphine-equivalents milligrams of opioid pain medication the patient has taken as an inpatient and after discharge from hospital (NCT03861988)
Timeframe: Post-intervention days 1, 2, 3, 5, 7 and 14
| Intervention | milligram morphine equivalents (Mean) | ||
|---|---|---|---|
| Day 1 | Day 2 | Day 3 | |
| Open Label Ketamine | 108.5 | 249.3 | 361.5 |
This outcome measures how many cumulative morphine-equivalents milligrams of opioid pain medication the patient has taken as an inpatient and after discharge from hospital (NCT03861988)
Timeframe: Post-intervention days 1, 2, 3, 5, 7 and 14
| Intervention | milligram morphine equivalents (Mean) | |||||
|---|---|---|---|---|---|---|
| Day 1 | Day 2 | Day 3 | Day 5 | Day 7 | Day 14 | |
| Double Blind Ketamine | 60.9 | 104.6 | 137.9 | 150.6 | 171.6 | 206.1 |
| Double Blind Placebo | 56.1 | 107.7 | 144.3 | 156.2 | 163.3 | 186.4 |
This outcome measures self-reported symptoms of anxiety and depression on a scale that ranges from 0 to 42. A lower score indicates lower severity of symptoms. (NCT03861988)
Timeframe: Post-intervention days 1, 2, 3, 5, 7 and 14
| Intervention | score on a scale (Mean) | |||||
|---|---|---|---|---|---|---|
| Day 1 | Day 2 | Day 3 | Day 5 | Day 7 | Day 14 | |
| Double Blind Ketamine | 17.8 | 18.8 | 19.3 | 18.3 | 18.4 | 16.4 |
| Double Blind Placebo | 19.9 | 21.2 | 20.8 | 18.9 | 19.6 | 17.2 |
| Open Label Ketamine | 14.8 | 22.6 | 13.0 | 16.6 | 19.2 | 14.0 |
The MADRS is a 10-item scale for the evaluation of depressive symptoms (Montgomery et al 1979). Each MADRS item is rated on a 0 to 6 scale. Total score range from 0-60, where lower MADRS scores indicate lower levels of depressive symptoms. The assessment for this outcome will be taken once daily on days 1, 2 and 3 post procedure. A mixed model for repeated measures (MMRM) was used to analyze the difference in postoperative MADRS score between ketamine and placebo groups.. (NCT03861988)
Timeframe: Post-intervention days 1, 2 and 3
| Intervention | score on a scale (Mean) | ||
|---|---|---|---|
| Day 1 | Day 2 | Day 3 | |
| Double Blind Ketamine | 12.7 | 15.1 | 17.0 |
| Double Blind Placebo | 16.4 | 17.5 | 17.2 |
| Open Label Ketamine | 17.0 | 25.4 | 10.5 |
Clinical response defined as >=50% reduction in MADRS score from baseline. MADRS score range: 0 to 60, a lower score indicates lower severity of symptoms. (NCT03861988)
Timeframe: Post-intervention days 1, 2 and 3
| Intervention | Participants (Count of Participants) | ||
|---|---|---|---|
| Day 1 | Day 2 | Day 3 | |
| Double Blind Ketamine | 12 | 10 | 9 |
| Double Blind Placebo | 10 | 12 | 10 |
| Open Label Ketamine | 2 | 1 | 3 |
24 reviews available for mianserin and Depression
| Article | Year |
|---|---|
Mirtazapine-induced Acute Pancreatitis in Patients With Depression: A Systematic Review.
Topics: Acute Disease; Antidepressive Agents; Antidepressive Agents, Tricyclic; Depression; Female; Humans; | 2023 |
Pharmacological interventions for treatment-resistant depression in adults.
Topics: Antidepressive Agents; Antipsychotic Agents; Depression; Drug Resistance; Drug Therapy, Combination; | 2019 |
Sertraline and mirtazapine as geriatric antidepressants.
Topics: Aged; Antidepressive Agents; Depression; Geriatric Psychiatry; Humans; Mianserin; Mirtazapine; Pract | 2013 |
Mirtazapine as positive control drug in studies examining the effects of antidepressants on driving ability.
Topics: Antidepressive Agents, Tricyclic; Automobile Driving; Computer Simulation; Depression; Dose-Response | 2015 |
Empirically Supported Use of Psychiatric Medications in Adolescents and Adults with IBD.
Topics: Adolescent; Adult; Affect; Anti-Anxiety Agents; Antidepressive Agents, Tricyclic; Anxiety; Bupropion | 2016 |
[Mirtazapine--pharmacologic action and clinical advantages].
Topics: Adrenergic alpha-Antagonists; Anti-Anxiety Agents; Antidepressive Agents, Second-Generation; Depress | 2009 |
[Depression].
Topics: Antidepressive Agents; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; C | 2010 |
[The effects of antidepressants on sleep in depressed patients with particular reference to trazodone in comparison to agomelatine, amitriptyline, doxepin, mianserine and mirtazapine].
Topics: Amitriptyline; Antidepressive Agents; Depression; Doxepin; Humans; Mianserin; Mirtazapine; Sleep; Sl | 2011 |
Mirtazapine versus other antidepressive agents for depression.
Topics: Adult; Antidepressive Agents; Antidepressive Agents, Tricyclic; Cyclohexanols; Depression; Humans; M | 2011 |
Enantiomers' potential in psychopharmacology--a critical analysis with special emphasis on the antidepressant escitalopram.
Topics: Animals; Antidepressive Agents, Second-Generation; Citalopram; Depression; Fluoxetine; Humans; Menta | 2002 |
New formulations of existing antidepressants: advantages in the management of depression.
Topics: Animals; Antidepressive Agents; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tri | 2004 |
[Suspected depression].
Topics: Adult; Amitriptyline; Antidepressive Agents; Antidepressive Agents, Second-Generation; Antidepressiv | 2006 |
[Biochemical aspects of using antidepressants in late middle age and the elderly (review)].
Topics: Age Factors; Aged; Aging; Antidepressive Agents; Catechol O-Methyltransferase; Depression; Depressiv | 1983 |
On the mode of action of mianserin.
Topics: Animals; Behavior, Animal; Brain; Depression; Dibenzazepines; Humans; Mianserin; Norepinephrine; Rat | 1982 |
Serotonin antagonists.
Topics: Cyproheptadine; Depression; Ergotamine; Humans; Hypertension; Ketanserin; Lisuride; Methysergide; Mi | 1984 |
Pharmacological properties of some "second generation" antidepressant drugs.
Topics: Animals; Antidepressive Agents; Brompheniramine; Depression; Electroconvulsive Therapy; Humans; Mian | 1980 |
Maprotiline, nomifensine, mianserin, zimelidine: a review of antidepressant efficacy in in-patients.
Topics: Antidepressive Agents; Brompheniramine; Clinical Trials as Topic; Depression; Humans; Maprotiline; M | 1980 |
The management of depression. Part 2. The place of the new antidepressants.
Topics: Antidepressive Agents; Antidepressive Agents, Tricyclic; Benzamides; Depression; Drug Interactions; | 1994 |
A risk-benefit assessment of mirtazapine in the treatment of depression.
Topics: Adult; Aged; Antidepressive Agents, Tricyclic; Depression; Depressive Disorder; Depressive Disorder, | 1997 |
Mirtazapine--another new class of antidepressant.
Topics: Adrenergic alpha-Antagonists; Antidepressive Agents, Tricyclic; Depression; Histamine H1 Antagonists | 1999 |
[Treatment of depression and cost efficiency. The cost of a tablet is a poor indicator seen from a socioeconomic perspective].
Topics: Adrenergic alpha-Agonists; Amitriptyline; Antidepressive Agents, Second-Generation; Antidepressive A | 2000 |
Mirtazapine. A pharmacoeconomic review of its use in depression.
Topics: Amitriptyline; Antidepressive Agents, Tricyclic; Depression; Humans; Mianserin; Mirtazapine; Quality | 2000 |
Mianserin: a review of its pharmacological properties and therapeutic efficacy in depressive illness.
Topics: Amitriptyline; Animals; Antidepressive Agents; Carbohydrate Metabolism; Cardiovascular Diseases; Dep | 1978 |
Pharmacology of locus coeruleus spontaneous and sensory-evoked activity.
Topics: 1-Naphthylamine; Action Potentials; Animals; Antidepressive Agents; Corticotropin-Releasing Hormone; | 1991 |
83 trials available for mianserin and Depression
| Article | Year |
|---|---|
Validating pre-treatment body mass index as moderator of antidepressant treatment outcomes: Findings from CO-MED trial.
Topics: Adult; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Biomarkers; Body | 2018 |
Study of the use of antidepressants for depression in dementia: the HTA-SADD trial--a multicentre, randomised, double-blind, placebo-controlled trial of the clinical effectiveness and cost-effectiveness of sertraline and mirtazapine.
Topics: Aged; Antidepressive Agents; Antidepressive Agents, Tricyclic; Cost-Benefit Analysis; Dementia; Depr | 2013 |
Unstimulated and glucose-stimulated ghrelin in depressed patients and controls.
Topics: Adult; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Appetite Regulati | 2014 |
A single dose of mirtazapine attenuates neural responses to self-referential processing.
Topics: Adolescent; Adult; Antidepressive Agents, Tricyclic; Cerebral Cortex; Depression; Emotions; Female; | 2016 |
Mirtazapine added to selective serotonin reuptake inhibitors for treatment-resistant depression in primary care (MIR trial): study protocol for a randomised controlled trial.
Topics: Antidepressive Agents, Tricyclic; Clinical Protocols; Depression; Drug Resistance; Humans; Mianserin | 2016 |
Efficacy of mirtazapine for the treatment of fibromyalgia without concomitant depression: a randomized, double-blind, placebo-controlled phase IIa study in Japan.
Topics: Adult; Analysis of Variance; Antidepressive Agents, Tricyclic; Depression; Double-Blind Method; Fema | 2016 |
Beneficial effects of antidepressant mirtazapine in functional dyspepsia patients with weight loss.
Topics: Adiposity; Adult; Affect; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic | 2016 |
Mirtazapine in comorbid major depression and an alcohol use disorder: A double-blind placebo-controlled pilot trial.
Topics: Adult; Alcohol Drinking; Alcohol-Related Disorders; Antidepressive Agents; Comorbidity; Depression; | 2016 |
Mirtazapine in comorbid major depression and an alcohol use disorder: A double-blind placebo-controlled pilot trial.
Topics: Adult; Alcohol Drinking; Alcohol-Related Disorders; Antidepressive Agents; Comorbidity; Depression; | 2016 |
Mirtazapine in comorbid major depression and an alcohol use disorder: A double-blind placebo-controlled pilot trial.
Topics: Adult; Alcohol Drinking; Alcohol-Related Disorders; Antidepressive Agents; Comorbidity; Depression; | 2016 |
Mirtazapine in comorbid major depression and an alcohol use disorder: A double-blind placebo-controlled pilot trial.
Topics: Adult; Alcohol Drinking; Alcohol-Related Disorders; Antidepressive Agents; Comorbidity; Depression; | 2016 |
FKBP5 polymorphisms and antidepressant response in geriatric depression.
Topics: Aged; Antidepressive Agents; Depression; Double-Blind Method; Female; Genetic Variation; Geriatrics; | 2010 |
Efficacy, tolerability, and preference of mirtazapine orally disintegrating tablets in depressed patients: a 17-week naturalistic study in Lithuania.
Topics: Administration, Oral; Adult; Aged; Antidepressive Agents, Tricyclic; Antipsychotic Agents; Benzodiaz | 2009 |
Venlafaxine and mirtazapine treatment lowers serum concentrations of dehydroepiandrosterone-sulfate in depressed patients remitting during the course of treatment.
Topics: Adult; Age Factors; Aged; Analysis of Variance; Antidepressive Agents; Case-Control Studies; Cyclohe | 2010 |
Antidepressive effect of mirtazapine in post-myocardial infarction depression is associated with soluble TNF-R1 increase: data from the MIND-IT.
Topics: Adult; Aged; Antidepressive Agents, Tricyclic; Depression; Female; Humans; Inflammation Mediators; M | 2011 |
Add-on mirtazapine improves depressive symptoms in schizophrenia: a double-blind randomized placebo-controlled study with an open-label extension phase.
Topics: Adolescent; Adult; Aged; Antidepressive Agents, Tricyclic; Antipsychotic Agents; Depression; Double- | 2011 |
Cost-effectiveness analyses for mirtazapine and sertraline in dementia: randomised controlled trial.
Topics: Antidepressive Agents; Caregivers; Cost-Benefit Analysis; Dementia; Depression; Health Care Costs; H | 2013 |
Leptin plasma concentrations increase during antidepressant treatment with amitriptyline and mirtazapine, but not paroxetine and venlafaxine: leptin resistance mediated by antihistaminergic activity?
Topics: Adult; Aged; Aged, 80 and over; Amitriptyline; Analysis of Variance; Antidepressive Agents; Biomarke | 2013 |
Complaints of poststroke insomnia and its treatment with mianserin.
Topics: Age Factors; Aged; Antidepressive Agents, Second-Generation; Depression; Dose-Response Relationship, | 2003 |
Poststroke depression: an 18-month follow-up.
Topics: Antidepressive Agents, Second-Generation; Depression; Female; Follow-Up Studies; Humans; Male; Mians | 2003 |
The apolipoprotein E epsilon4 allele and antidepressant efficacy in cognitively intact elderly depressed patients.
Topics: Aged; Aged, 80 and over; Alleles; Antidepressive Agents; Apolipoproteins E; Chromatography, High Pre | 2003 |
Open trial of mirtazapine in patients with fibromyalgia.
Topics: Adrenergic alpha-Antagonists; Adult; Depression; Drug Administration Schedule; Female; Fibromyalgia; | 2004 |
Changes of sleep architecture, spectral composition of sleep EEG, the nocturnal secretion of cortisol, ACTH, GH, prolactin, melatonin, ghrelin, and leptin, and the DEX-CRH test in depressed patients during treatment with mirtazapine.
Topics: Adrenocorticotropic Hormone; Adult; Animals; Antidepressive Agents, Tricyclic; Area Under Curve; Bod | 2006 |
Mirtazapine naturalistic depression study (in Sweden)--MINDS(S): clinical efficacy and safety.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antidepressive Agents, Tricyclic; Body Mass Index; Depre | 2006 |
Effects of combination treatment with mood stabilizers and mirtazapine on plasma concentrations of neuroactive steroids in depressed patients.
Topics: Adult; Antidepressive Agents, Tricyclic; Depression; Drug Therapy, Combination; Female; Humans; Lith | 2007 |
Maprotiline, nomifensine, mianserin, zimelidine: a review of antidepressant efficacy in in-patients.
Topics: Antidepressive Agents; Brompheniramine; Clinical Trials as Topic; Depression; Humans; Maprotiline; M | 1980 |
The clinical efficacy and side-effects of mianserin and nortriptyline in depressed out-patients: a double-blind randomized trial.
Topics: Adult; Aged; Ambulatory Care; Clinical Trials as Topic; Depression; Depressive Disorder; Dibenzazepi | 1982 |
The use of mianserin in the treatment of depression.
Topics: Aged; Clinical Trials as Topic; Depression; Dibenzazepines; Double-Blind Method; Female; Humans; Mia | 1980 |
Mianserin and clomipramine in the treatment of depression.
Topics: Adult; Aged; Clinical Trials as Topic; Clomipramine; Depression; Dibenzazepines; Double-Blind Method | 1982 |
A double-blind study of trazodone and mianserin in the treatment of depression in general practice.
Topics: Adolescent; Adult; Aged; Clinical Trials as Topic; Depression; Diazepam; Dibenzazepines; Dose-Respon | 1982 |
A double-blind controlled trial of mianserin and amitriptyline in depression.
Topics: Adolescent; Adult; Aged; Amitriptyline; Delayed-Action Preparations; Depression; Dibenzazepines; Dou | 1980 |
A double-blind group comparative trial of mianserin and diazepam in depressed outpatients.
Topics: Adolescent; Adult; Depression; Diazepam; Dibenzazepines; Double-Blind Method; Female; Humans; Male; | 1980 |
Chronic tension-type headache, mood depression and serotonin: therapeutic effects of fluvoxamine and mianserine.
Topics: Adult; Chronic Disease; Depression; Double-Blind Method; Female; Fluvoxamine; Headache; Humans; Male | 1994 |
[A controlled study of the prophylactic effect of mianserin and placebo in recurrent depression].
Topics: Adult; Depression; Double-Blind Method; Female; Humans; Male; Mianserin; Middle Aged; Premedication; | 1993 |
Enantioselective determination of mianserin and its desmethyl metabolite in plasma during treatment of depressed Japanese patients.
Topics: Adult; Aged; Antidepressive Agents, Second-Generation; Chromatography, High Pressure Liquid; Depress | 1995 |
Prevention of poststroke depression: 1 year randomised placebo controlled double blind trial of mianserin with 6 month follow up after therapy.
Topics: Adult; Antidepressive Agents, Second-Generation; Cerebrovascular Disorders; Depression; Depressive D | 1999 |
Depressed in-patients respond differently to imipramine and mirtazapine.
Topics: Adrenergic alpha-Antagonists; Adult; Analysis of Variance; Antidepressive Agents, Tricyclic; Anxiety | 1999 |
Lack of drug interactions between mirtazapine and risperidone in psychiatric patients: a pilot study.
Topics: Adult; Aged; Antidepressive Agents, Tricyclic; Antipsychotic Agents; Depression; Depressive Disorder | 1999 |
[Comparative efficacy of remeron (mirtazapine) and amitriptyline in treatment of patients with depression of moderate intensity].
Topics: Adrenergic alpha-Antagonists; Adult; Amitriptyline; Antidepressive Agents, Tricyclic; Depression; Hi | 2000 |
An open trial of mirtazapine in menopausal women with depression unresponsive to estrogen replacement therapy.
Topics: Adult; Antidepressive Agents; Depression; Estradiol; Female; Hormone Replacement Therapy; Humans; Me | 2001 |
An open-label, crossover trial of mirtazapine (15 and 30 mg) in cancer patients with pain and other distressing symptoms.
Topics: Antidepressive Agents, Tricyclic; Cross-Over Studies; Depression; Dose-Response Relationship, Drug; | 2002 |
An open-label, crossover trial of mirtazapine (15 and 30 mg) in cancer patients with pain and other distressing symptoms.
Topics: Antidepressive Agents, Tricyclic; Cross-Over Studies; Depression; Dose-Response Relationship, Drug; | 2002 |
An open-label, crossover trial of mirtazapine (15 and 30 mg) in cancer patients with pain and other distressing symptoms.
Topics: Antidepressive Agents, Tricyclic; Cross-Over Studies; Depression; Dose-Response Relationship, Drug; | 2002 |
An open-label, crossover trial of mirtazapine (15 and 30 mg) in cancer patients with pain and other distressing symptoms.
Topics: Antidepressive Agents, Tricyclic; Cross-Over Studies; Depression; Dose-Response Relationship, Drug; | 2002 |
[New strategies in psychiatric diagnosis through the use of audio-visual technics. 2. Importance of verbal and non-verbal information for assessment of depressive patients].
Topics: Amitriptyline; Antidepressive Agents; Audiovisual Aids; Depression; Humans; Methods; Mianserin | 1976 |
Autonomic actions and interactions of mianserin hydrochloride (Org. GB 94) and amitriptyline in patients with depressive illness.
Topics: Amitriptyline; Autonomic Nervous System; Blood Pressure; Clinical Trials as Topic; Depression; Diben | 1976 |
[Results of a field trial with a new anti-depressive compound in ambulatory and hospitalized patients (author's transl)].
Topics: Adolescent; Adult; Aged; Ambulatory Care; Clinical Trials as Topic; Depression; Dibenzazepines; Drug | 1977 |
[Mianserin and imipramin in depressive conditions (author's transl)].
Topics: Adult; Clinical Trials as Topic; Depression; Dibenzazepines; Drug Evaluation; Female; Humans; Imipra | 1977 |
Effect of mianserin hydrochloride on peripheral uptake mechanisms for noradrenaline and 5-hydroxytryptamine in man.
Topics: Antidepressive Agents; Bethanidine; Blood Platelets; Clinical Trials as Topic; Depression; Dibenzaze | 1978 |
Cardiovascular responses to mianserin hydrochloride: a comparison with tricyclic antidepressant drugs.
Topics: Adult; Amitriptyline; Antidepressive Agents, Tricyclic; Bethanidine; Blood Pressure; Cardiovascular | 1978 |
Electroencephalogram study of mianserin in depressed patients.
Topics: Adolescent; Adult; Aged; Brain; Clinical Trials as Topic; Depression; Dibenzazepines; Dose-Response | 1978 |
Comparative double-blind trial of mianserin hydrochloride (Organon GB94) and diazepam in patients with depressive illness.
Topics: Adjustment Disorders; Adolescent; Adult; Aged; Clinical Trials as Topic; Depression; Diazepam; Diben | 1978 |
Relationship between mianserin plasma levels and antidepressant effect in a double-blind trial comparing a single night-time and divided daily dose regimens.
Topics: Adult; Clinical Trials as Topic; Depression; Dibenzazepines; Double-Blind Method; Drug Administratio | 1978 |
Differential effects on suicidal ideation of mianserin, maprotiline and amitriptyline.
Topics: Adult; Amitriptyline; Anthracenes; Clinical Trials as Topic; Depression; Dibenzazepines; Double-Blin | 1978 |
Mianserin in the treatment of depressive illness and anxiety states in general practice.
Topics: Adolescent; Adult; Anxiety; Clinical Trials as Topic; Depression; Diazepam; Dibenzazepines; Double-B | 1978 |
A double-blind multicentre trial comparing mianserin with imipramine.
Topics: Adjustment Disorders; Adolescent; Adult; Affective Disorders, Psychotic; Aged; Clinical Trials as To | 1978 |
Mianserin hydrochloride: a new anti-depressant drug.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Clinical Trials as Topic; Depression; Dibenzazepines | 1978 |
A comparative clinical trial of mianserin (Norval) and amitriptyline in the treatment of depression in general practice.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clinical Trials as Topic; Depression; Dibenzazepines; Double | 1978 |
Mianserin and lithium in the prophylaxis of depression.
Topics: Administration, Oral; Adult; Aged; Clinical Trials as Topic; Depression; Dibenzazepines; Double-Blin | 1978 |
Three double-blind comparative trials of mianserine (ORG GB 94) and amitriptyline in the treatment of depressive illness.
Topics: Adolescent; Adult; Alanine Transaminase; Alkaline Phosphatase; Amitriptyline; Aspartate Aminotransfe | 1977 |
A comparison of the cardiac effects of mianserin and amitriptyline in man.
Topics: Adult; Amitriptyline; Clinical Trials as Topic; Depression; Dibenzazepines; Electrocardiography; Fem | 1977 |
[A new antidepressive agent. Mianserin hydrochloride (Tolvin)].
Topics: Amitriptyline; Clinical Trials as Topic; Depression; Dibenzazepines; Humans; Mianserin | 1978 |
Mianserin--a study of different dosage regimes in psychiatric outpatients.
Topics: Adolescent; Adult; Clinical Trials as Topic; Depression; Dibenzazepines; Drug Administration Schedul | 1979 |
[Clinical evaluation of the ORG GB 94 in the treatment of depression].
Topics: Adolescent; Adult; Clinical Trials as Topic; Depression; Dibenzazepines; Drug Evaluation; Female; He | 1978 |
Mianserin--a new tetracyclic antidepressant.
Topics: Clinical Trials as Topic; Depression; Dibenzazepines; Humans; Mianserin | 1979 |
Mianserin in the treatment of depressive illness: a comparison with amitriptyline.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clinical Trials as Topic; Depression; Dibenzazepines; Double | 1979 |
[Therapeutical effect of mianserin and imipramine in endogenous depressions (controlled comparison) (author's transl)].
Topics: Adolescent; Adult; Aged; Clinical Trials as Topic; Depression; Dibenzazepines; Double-Blind Method; | 1979 |
[Comparison of the effects of lofepramin and mianserin in depressed patients in a double blind trial].
Topics: Adult; Aged; Clinical Trials as Topic; Depression; Dibenzazepines; Double-Blind Method; Female; Huma | 1979 |
[Treatment of depression. Comparative study on the effects of mianserin (Tolvin) and amitriptyline].
Topics: Adolescent; Adult; Aged; Amitriptyline; Depression; Dibenzazepines; Female; Humans; Male; Mianserin; | 1979 |
Workshop on the clinical pharmacology and efficacy of mianserin.
Topics: Animals; Brain; Depression; Dibenzazepines; Drug Interactions; Female; Heart; Humans; Mianserin; Mid | 1978 |
[Mianserin (Tolvin) in the management of glaucoma patients with depression].
Topics: Adolescent; Adult; Aged; Depression; Dibenzazepines; Glaucoma; Humans; Intraocular Pressure; Mianser | 1978 |
Proceedings: Mianserin vs. amitriptyline--a double-blind-trial evaluated by the AMP-system.
Topics: Amitriptyline; Clinical Trials as Topic; Depression; Dibenzazepines; Humans; Mianserin | 1975 |
Mianserin versus amitriptyline. A double-blind-trial evaluated by the AMP system.
Topics: Amitriptyline; Circadian Rhythm; Clinical Trials as Topic; Depression; Dibenzazepines; Electroenceph | 1976 |
[New diagnostic strategies in psychiatry by means of video-technique. I. The use of time-blind video analysis for the evaluation of antidepressant drug trials (author's transl)].
Topics: Amitriptyline; Clinical Trials as Topic; Depression; Dibenzazepines; Drug Evaluation; Female; Humans | 1976 |
Time-blind analysis of TV-stored interviews. An objective method to study antidepressive drug-effects.
Topics: Amitriptyline; Antidepressive Agents, Tricyclic; Clinical Trials as Topic; Depression; Drug Evaluati | 1976 |
Mianserin in the treatment of depression in general practice.
Topics: Adolescent; Adult; Aged; Clinical Trials as Topic; Depression; Dibenzazepines; Female; Humans; Imipr | 1976 |
Controlled clinical trial of a new antidepressant (Org. GB 94) of novel chemical formulation.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clinical Trials as Topic; Depression; Dibenzazepines; Female | 1975 |
[Studies with a behavior-oriented evaluation scale for depressive inhibition and agitation. Results of a video-documented amitriptyline-mianserine study].
Topics: Amitriptyline; Anxiety; Depression; Female; Humans; Inhibition, Psychological; Mianserin; Psychologi | 1976 |
[Therapeutic efficacy of tricyclic and antidepressive agents. Comparative double blind test of amitriptyline and mianserin (Org GB 94)].
Topics: Adolescent; Adult; Aged; Amitriptyline; Depression; Dibenzazepines; Drug Evaluation; Female; Humans; | 1976 |
The effects of psychomotor performance of fluvoxamine versus mianserin in depressed patients in general practice.
Topics: Adolescent; Adult; Aged; Depression; Double-Blind Method; Female; Fluvoxamine; Humans; Male; Mianser | 1991 |
A double-blind group comparison of mianserin and clomipramine in the treatment of mildly depressed psychiatric out-patients.
Topics: Adult; Anti-Anxiety Agents; Anxiety; Clomipramine; Depression; Dibenzazepines; Female; Humans; Male; | 1985 |
The drug treatment of depression in general practice: a comparison of nocte administration of trazodone with mianserin, dothiepin and amitriptyline.
Topics: Adolescent; Adult; Aged; Amitriptyline; Antidepressive Agents; Clinical Trials as Topic; Depression; | 1988 |
The efficacy and residual effects of trazodone (150 mg nocte) and mianserin in the treatment of depressed general practice patients.
Topics: Adolescent; Adult; Aged; Clinical Trials as Topic; Depression; Double-Blind Method; Drug Tolerance; | 1988 |
Mianserin and trazodone for cardiac patients with depression.
Topics: Adult; Aged; Clinical Trials as Topic; Depression; Double-Blind Method; Female; Heart Diseases; Hemo | 1988 |
Interpreting significance in an antidepressant drug trial.
Topics: Adult; Clinical Trials as Topic; Depression; Dibenzothiepins; Dothiepin; Female; Humans; Male; Mians | 1987 |
A double-blind comparison of once-daily flupenthixol and mianserin in depressed hospital out-patients.
Topics: Administration, Oral; Adolescent; Adult; Aged; Clinical Trials as Topic; Depression; Dibenzazepines; | 1986 |
Antidepressant drugs and migraine.
Topics: Adult; Amitriptyline; Antidepressive Agents, Tricyclic; Clinical Trials as Topic; Depression; Female | 1985 |
Treatment of depression in cancer patients.
Topics: Amitriptyline; Breast Neoplasms; Clinical Trials as Topic; Combined Modality Therapy; Depression; Fe | 1985 |
Efficacy and safety of mianserin in the treatment of depression of women with cancer.
Topics: Adult; Aged; Clinical Trials as Topic; Depression; Dibenzazepines; Female; Humans; Mianserin; Middle | 1985 |
152 other studies available for mianserin and Depression
| Article | Year |
|---|---|
Novel multitarget 5-arylidenehydantoins with arylpiperazinealkyl fragment: Pharmacological evaluation and investigation of cytotoxicity and metabolic stability.
Topics: Animals; Antidepressive Agents; Depression; Disease Models, Animal; Humans; Receptors, Serotonin; St | 2019 |
Asymptomatic syndrome of inappropriate secretion of antidiuretic hormone (SIADH) following duloxetine treatment for pain with depression: Two case reports.
Topics: Aged; Aged, 80 and over; Depression; Duloxetine Hydrochloride; Female; Humans; Hyponatremia; Inappro | 2022 |
Treatment-Resistant Depression (TRD): Is the Opioid System Involved?
Topics: Analgesics, Opioid; Animals; Antidepressive Agents; Depression; Dose-Response Relationship, Drug; Fl | 2023 |
Antidepressants Differentially Regulate Intracellular Signaling from α1-Adrenergic Receptor Subtypes In Vitro.
Topics: Animals; Antidepressive Agents; Citalopram; Depression; Desipramine; Fluoxetine; Gene Expression Reg | 2021 |
Mirtazapine Induces Nightmares in Depressed Patients.
Topics: Antidepressive Agents, Tricyclic; Depression; Dreams; Humans; Male; Mianserin; Middle Aged; Mirtazap | 2017 |
Translating the HAM-D into the MADRS and vice versa with equipercentile linking.
Topics: Adult; Antidepressive Agents, Tricyclic; Depression; Depressive Disorder, Major; Female; Humans; Mal | 2018 |
The impact of depression and antidepressant usage on primary biliary cholangitis clinical outcomes.
Topics: Aged; Antidepressive Agents; Bile Ducts; Cholagogues and Choleretics; Cholangitis; Cohort Studies; D | 2018 |
Tachyphylaxis to the Sedative Action of Mirtazapine.
Topics: Adult; Antidepressive Agents, Tricyclic; Conscious Sedation; Depression; Dose-Response Relationship, | 2018 |
Influence of body mass index on the choice of therapy for depression and follow-up care.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Body Mass Index; Choice Behavior; Cohort Studies; De | 2013 |
Effect of co-treatment with fluoxetine or mirtazapine and risperidone on the active behaviors and plasma corticosterone concentration in rats subjected to the forced swim test.
Topics: Animals; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Antipsychotic A | 2012 |
Prenatal antidepressant exposure and risk of spontaneous abortion - a population-based study.
Topics: Abortion, Spontaneous; Adult; Antidepressive Agents; Cyclohexanols; Depression; Duloxetine Hydrochlo | 2013 |
Side effects of interferon therapy in adolescent melanoma.
Topics: Adolescent; Adrenergic alpha-Antagonists; Depression; Humans; Immunologic Factors; Interferon-alpha; | 2014 |
[Antidepressant treatment associated hyponatremia -- case report].
Topics: Aged; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Critical Care; Cyc | 2013 |
Does use of tetracyclic antidepressant-mirtazapine reduce cancer risk in depression patients?
Topics: Adult; Age Factors; Aged; Antidepressive Agents; Case-Control Studies; Chi-Square Distribution; Como | 2013 |
Linking Clostridium difficile infection with depression.
Topics: Antidepressive Agents; Clostridioides difficile; Clostridium Infections; Depression; Fluoxetine; Hum | 2013 |
Impact of antidepressants on cytokine production of depressed patients in vitro.
Topics: Adult; Antidepressive Agents; CD40 Antigens; Citalopram; Cytokines; Depression; Female; Humans; Inte | 2013 |
[Use of psychotropic drugs in patients with chronic pain].
Topics: Chronic Pain; Cortisone; Depression; Guillain-Barre Syndrome; Humans; Mianserin; Middle Aged; Mirtaz | 2014 |
The depressogenic-like effect of acute and chronic treatment with dexamethasone and its influence on the activity of antidepressant drugs in the forced swim test in adult mice.
Topics: Amitriptyline; Animals; Antidepressive Agents; Citalopram; Depression; Dexamethasone; Dose-Response | 2014 |
Use of antidepressants and association with elective termination of pregnancy: population based case-control study.
Topics: Abortion, Induced; Adult; Antidepressive Agents; Antidepressive Agents, Tricyclic; Case-Control Stud | 2015 |
Treatment of depression in an adolescent with cardiomyopathy and arrhythmia.
Topics: Adolescent; Antidepressive Agents, Tricyclic; Anxiety; Cardiomyopathy, Hypertrophic; Depression; Ele | 2015 |
An unusual presentation of dose dependent SIADH secondary to mirtazapine therapy.
Topics: Aged; Antidepressive Agents; Citalopram; Depression; Dose-Response Relationship, Drug; Humans; Inapp | 2015 |
Antidepressant action via the nitric oxide system: A pilot study in an acute depressive model induced by arginin.
Topics: Acute Disease; Adrenergic Uptake Inhibitors; Animals; Antidepressive Agents; Arginine; Cyclopropanes | 2015 |
Effect of lipid emulsion during resuscitation of a patient with cardiac arrest after overdose of chlorpromazine and mirtazapine.
Topics: Antidepressive Agents, Tricyclic; Antipsychotic Agents; Cardiopulmonary Resuscitation; Chlorpromazin | 2015 |
Antidepressant Prescription Pattern in the Presence of Medical Co-morbidity: REAP-AD 2013 Study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antidepressive Agents; Antidepressive Agents, Tricyclic; | 2015 |
Mirtazapine-Associated Hypertriglyceridemia and Hyperglycemia.
Topics: Aged; Antidepressive Agents, Tricyclic; Depression; Humans; Hyperglycemia; Hypertriglyceridemia; Mal | 2015 |
Effect of Mirtazapine Treatment on Serum Levels of Brain-Derived Neurotrophic Factor and Tumor Necrosis Factor-α in Patients of Major Depressive Disorder with Severe Depression.
Topics: Adolescent; Adult; Antidepressive Agents, Tricyclic; Brain-Derived Neurotrophic Factor; Depression; | 2016 |
Comparative Evaluation of Partial α2 -Adrenoceptor Agonist and Pure α2 -Adrenoceptor Antagonist on the Behavioural Symptoms of Withdrawal after Chronic Alcohol Administration in Mice.
Topics: Adrenergic alpha-2 Receptor Agonists; Adrenergic alpha-Antagonists; Alcoholism; Animals; Anxiety; Be | 2016 |
The Effects of Antidepressants and Quetiapine on Heart Rate Variability.
Topics: Adult; Aged; Antidepressive Agents; Anxiety; Depression; Female; Heart Rate; Humans; Linear Models; | 2016 |
Traxoprodil augments the antidepressant-like activity of agomelatine but not of mianserin or tianeptine in the forced swim test in mice.
Topics: Acetamides; Animals; Antidepressive Agents; Brain; Depression; Depressive Disorder; Drug Synergism; | 2016 |
Probable Serotonin Syndrome and Withdrawal Symptoms Caused by Milnacipran.
Topics: Aged; Antidepressive Agents; Cerebral Hemorrhage; Cyclopropanes; Depression; Drug Substitution; Fema | 2016 |
Successful antidepressive treatment with mirtazapine following lung transplantation.
Topics: Adult; Antidepressive Agents, Tricyclic; Depression; Humans; Lung Transplantation; Male; Mianserin; | 2008 |
[Integrative therapy of a patient with complex psychosomatic complaints].
Topics: Aged; Antidepressive Agents, Tricyclic; Depression; Dyspepsia; Female; Humans; Integrative Medicine; | 2008 |
Mirtazapine associated with profound hyponatremia: two case reports.
Topics: Adverse Drug Reaction Reporting Systems; Aged; Antidepressive Agents, Tricyclic; Depression; Female; | 2008 |
Factors potentiating the risk of mirtazapine-associated restless legs syndrome.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Analgesics, Non-Narcotic; Antidepressive Agents, Tricycl | 2008 |
Mirtazapine-associated hyponatremia in an elderly patient.
Topics: Aged; Antidepressive Agents, Tricyclic; Depression; Female; Humans; Hypertension; Hyponatremia; Mian | 2009 |
Neopterin and C-reactive protein in the course of Stevens-Johnson syndrome: report of a case.
Topics: Anticonvulsants; Antidepressive Agents, Tricyclic; Biopsy; C-Reactive Protein; Depression; Drug Ther | 2009 |
Stevens-Johnson syndrome due to mirtazapine - first case.
Topics: Adult; Antidepressive Agents, Tricyclic; Depression; Humans; Male; Mianserin; Mirtazapine; Patch Tes | 2009 |
Leptin, adiponectin, leptin to adiponectin ratio and insulin resistance in depressive women.
Topics: Adiponectin; Adult; Aged; Antidepressive Agents; Blood Glucose; Body Mass Index; Chi-Square Distribu | 2009 |
Mania associated with mirtazepine treatment and mixed depression.
Topics: Antidepressive Agents, Tricyclic; Bipolar Disorder; Depression; Humans; Male; Mianserin; Middle Aged | 2010 |
Embryotoxicity of mirtazapine: a study using Chick Embryotoxicity Screening Test.
Topics: Abnormalities, Drug-Induced; Animals; Antidepressive Agents, Tricyclic; Chick Embryo; Depression; Do | 2010 |
Mirtazapine in combination with perospirone synergistically enhances dopamine release in the rat prefrontal cortex via 5-HT1A receptor activation.
Topics: Animals; Depression; Disease Models, Animal; Dopamine; Drug Resistance; Drug Synergism; Drug Therapy | 2011 |
Treatment of depression as part of end-of-life care.
Topics: Aged; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Carcinoma, Squamou | 2008 |
What do psychiatrists talk about with their depressed patients parallel to prescribing an antidepressant?
Topics: Adult; Aged; Aged, 80 and over; Antidepressive Agents; Combined Modality Therapy; Depression; Depres | 2011 |
FPIN's clinical inquiries: Antidepressants for the treatment of insomnia in patients with depression.
Topics: Amitriptyline; Antidepressive Agents; Antidepressive Agents, Tricyclic; Depression; Dose-Response Re | 2011 |
Mirtazapine as an alternative for selective-serotonin-reuptake-inhibitor-induced syndrome of inappropriate secretion of antidiuretic hormone.
Topics: Aged; Antidepressive Agents, Tricyclic; Depression; Humans; Inappropriate ADH Syndrome; Male; Mianse | 2012 |
Prolonged QTc interval and torsades de pointes induced by citalopram.
Topics: Adult; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Citalopram; Depre | 2012 |
Noradrenergic antidepressants increase cortical dopamine: potential use in augmentation strategies.
Topics: Adrenergic alpha-2 Receptor Antagonists; Adrenergic Uptake Inhibitors; Animals; Antidepressive Agent | 2012 |
Antidepressants and unresponsive episodes in the elderly.
Topics: Age Factors; Aged, 80 and over; Antidepressive Agents, Tricyclic; Depression; Guidelines as Topic; H | 2012 |
[Mirtazapine versus other antidepressive agents for depression].
Topics: Antidepressive Agents; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; D | 2012 |
Low-dose mirtazapine added to selective serotonin reuptake inhibitors in pregnant women with major depression or panic disorder including symptoms of severe nausea, insomnia and decreased appetite: three cases.
Topics: Adult; Antidepressive Agents, Tricyclic; Depression; Dose-Response Relationship, Drug; Feeding and E | 2013 |
Weight change in depressed nursing home patients on mirtazapine.
Topics: Aged; Antidepressive Agents, Tricyclic; Depression; Female; Homes for the Aged; Humans; Male; Mianse | 2002 |
Neutropenia associated with mirtazapine use: is a drop in the neutrophil count in a symptomatic older adults a cause for concern?
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Antidepressive Agents, Tricyclic; Depression; Female; Hu | 2002 |
Mirtazapine use in two pregnant women: is it safe?
Topics: Adult; Antidepressive Agents, Tricyclic; Anxiety; Depression; Drug Therapy, Combination; Female; Fol | 2002 |
In the rat forced swimming test, chronic but not subacute administration of dual 5-HT/NA antidepressant treatments may produce greater effects than selective drugs.
Topics: Adrenergic alpha-Agonists; Adrenergic Uptake Inhibitors; Animals; Antidepressive Agents, Second-Gene | 2002 |
Sleep-wake effects of meta-chlorophenyl piperazine and mianserin in the behaviorally depressed rat.
Topics: Animals; Behavior, Animal; Depression; Injections, Intraventricular; Male; Mianserin; Piperazines; R | 2002 |
Mirtazapine induces REM sleep behavior disorder (RBD) in parkinsonism.
Topics: Aged; Antidepressive Agents, Tricyclic; Depression; Electroencephalography; Humans; Levodopa; Male; | 2003 |
[Worsening of autosomal dominant restless legs syndrome after use of mirtazapine: case report].
Topics: Aged; Antidepressive Agents, Tricyclic; Depression; Female; Genes, Dominant; Humans; Mianserin; Mirt | 2002 |
Re: Mirtazapine in cancer patients.
Topics: Antidepressive Agents, Tricyclic; Depression; Female; Humans; Male; Mianserin; Middle Aged; Mirtazap | 2003 |
Mirtazapine: another drug responsible for drug-induced acute pancreatitis? A letter of warning.
Topics: Acute Disease; Adult; Antidepressive Agents, Tricyclic; Depression; Female; Humans; Mianserin; Mirta | 2003 |
Mirtazapine in suicidal Huntington's disease.
Topics: Adult; Antidepressive Agents, Tricyclic; Depression; Female; Humans; Huntington Disease; Mianserin; | 2003 |
Open space swimming test to index antidepressant activity.
Topics: Alanine; Animals; Antidepressive Agents; Behavior, Animal; Depression; Disease Models, Animal; Drug | 2003 |
Taurine concentration in human blood peripheral lymphocytes: major depression and treatment with the antidepressant mirtazapine.
Topics: Adolescent; Adult; Depression; Female; Humans; Lymphocytes; Male; Mianserin; Middle Aged; Mirtazapin | 2003 |
Chairmen's introduction.
Topics: Antidepressive Agents, Tricyclic; Depression; Humans; Mianserin; Mirtazapine; Patient Compliance; Pr | 2003 |
Mirtazapine-induced hyponatraemia.
Topics: Aged; Aged, 80 and over; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; | 2003 |
[Unclear chronic aches. Often depression plays a part therein].
Topics: Acetates; Amines; Analgesics, Opioid; Anti-Anxiety Agents; Antidepressive Agents; Antidepressive Age | 2003 |
[Enlargement of QT-interval in a patient with coronary disease treated with mianserin].
Topics: Aged; Antidepressive Agents, Second-Generation; Coronary Disease; Depression; Electrocardiography; F | 2003 |
Mirtazapine: not a dual action antidepressant?
Topics: Antidepressive Agents, Tricyclic; Depression; Humans; Mianserin; Mirtazapine; Serotonin; Synaptic Tr | 2004 |
Mechanism of action of mirtazapine: dual action or dual effect?
Topics: Antidepressive Agents, Tricyclic; Depression; Humans; Mianserin; Mirtazapine; Serotonin; Serotonin S | 2004 |
Study of mirtazapine antidepressant effects in rats.
Topics: Analysis of Variance; Animals; Antidepressive Agents; Depression; Disease Models, Animal; Drug Admin | 2005 |
Non-lethal mirtazapine overdose with rhabdomyolysis.
Topics: Adult; Antidepressive Agents, Tricyclic; Depression; Drug Overdose; Humans; Male; Mianserin; Mirtaza | 2005 |
36-Year-old woman with loss of consciousness, fever, and tachycardia.
Topics: Adult; Analgesics, Opioid; Antidepressive Agents, Tricyclic; Back Pain; Depression; Diagnosis, Diffe | 2005 |
The effect of mirtazapine in patients with chronic pain and concomitant depression.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antidepressive Agents, Tricyclic; Chronic Disease; Depre | 2006 |
A suspicious bathtub death in a suicidal patient on mirtazapine.
Topics: Antidepressive Agents, Tricyclic; Asphyxia; Depression; Diagnosis, Differential; Drowning; Female; F | 2006 |
Recurrent hyponatremia associated with citalopram and mirtazapine.
Topics: Aged; Antidepressive Agents; Antidepressive Agents, Tricyclic; Citalopram; Depression; Diagnosis, Di | 2006 |
[Compliance in psychiatry: results of a survey of depressed patients using orally disintegrating tablet].
Topics: Administration, Oral; Adult; Age Factors; Antidepressive Agents, Tricyclic; Chi-Square Distribution; | 2006 |
Cessation of complex visual hallucinations during treatment with mirtazapine.
Topics: Aged; Antidepressive Agents, Tricyclic; Depression; Female; Hallucinations; Humans; Mianserin; Middl | 2007 |
Mirtazapine for depression and comorbidities in older patients with cancer.
Topics: Aged; Antidepressive Agents, Tricyclic; Antiemetics; Comorbidity; Depression; Humans; Mianserin; Mir | 2007 |
Can prefrontal theta cordance differentiate between depression recovery and dissimulation?
Topics: Adult; Antidepressive Agents, Tricyclic; Depression; Fatal Outcome; Female; Humans; Mianserin; Mirta | 2007 |
[Differentiated approach to the therapy of endogenous anxious depression].
Topics: Adult; Antidepressive Agents, Tricyclic; Anxiety; Carbon Radioisotopes; Depression; Female; Follow-U | 2007 |
Enhancing effect of mirtazapine on cognitive functions associated with prefrontal cortex in patients with recurrent depression.
Topics: Adult; Aged; Analysis of Variance; Antidepressive Agents, Tricyclic; Case-Control Studies; Cognition | 2007 |
Unusual appetites in patients on mianserin.
Topics: Appetite; Body Weight; Depression; Dibenzazepines; Female; Humans; Male; Mianserin; Middle Aged | 1980 |
Interactions of anticonvulsant drugs with mianserin and nomifensine.
Topics: Adult; Anticonvulsants; Depression; Dibenzazepines; Drug Interactions; Humans; Isoquinolines; Mianse | 1981 |
Glossitis associated with mianserin.
Topics: Aged; Depression; Dibenzazepines; Female; Glossitis; Humans; Male; Mianserin; Middle Aged | 1984 |
Mianserin reduces plasma levels of beta-endorphin immunoreactivity in depressed patients.
Topics: Adult; beta-Endorphin; Depression; Dibenzazepines; Endorphins; Female; Humans; Male; Mianserin; Midd | 1982 |
Mianserin. An example of balancing benefits and risks in therapy.
Topics: Agranulocytosis; Cost-Benefit Analysis; Depression; Dibenzazepines; Humans; Joint Diseases; Kinetics | 1984 |
[Athymil].
Topics: Depression; Dibenzazepines; Humans; Mianserin | 1984 |
Mianserin and jaundice.
Topics: Adult; Cholestasis; Depression; Dibenzazepines; Female; Humans; Mianserin; Multiple Sclerosis | 1983 |
Postsynaptic serotonergic blockade following chronic antidepressive treatment with trazodone in an animal model of depression.
Topics: 5-Hydroxytryptophan; Amitriptyline; Animals; Depression; Disease Models, Animal; Humans; Male; Methy | 1984 |
Postsynaptic action by four antidepressive drugs in an animal model of depression.
Topics: 5-Hydroxytryptophan; Amitriptyline; Animals; Antidepressive Agents; Behavior, Animal; Depression; Di | 1981 |
The therapeutic profile of mianserin in mild elderly depressives [proceedings].
Topics: Aged; Amitriptyline; Depression; Dibenzazepines; Double-Blind Method; Humans; Mianserin; Placebos | 1981 |
A simplified method for the estimation of mianserin in plasma.
Topics: Depression; Dibenzazepines; Humans; Mianserin | 1981 |
Possible lack of anticholinergic effects with mianserin: a pilot study.
Topics: Adult; Depression; Dibenzazepines; Female; Humans; Male; Mianserin; Middle Aged; Receptors, Choliner | 1980 |
Possible use of mianserin in cases of unacceptable weight gain due to tricyclic anti-depressant therapy.
Topics: Adult; Amitriptyline; Body Weight; Depression; Dibenzazepines; Female; Humans; Mianserin | 1980 |
Effects of chronic mianserin administration on serotonin metabolism and receptors in the 5-hydroxytryptophan depression model.
Topics: 5-Hydroxytryptophan; 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Brain Chemistry; Cerebral Cort | 1994 |
Curative effects of the atypical antidepressant mianserin in the chronic mild stress-induced anhedonia model of depression.
Topics: Animals; Behavior, Animal; Depression; Male; Mianserin; Rats; Self Stimulation; Stress, Psychologica | 1994 |
Mianserin in breast milk.
Topics: Adult; Depression; Female; Humans; Lactation; Mianserin; Milk, Human; Postpartum Period | 1993 |
Steady-state plasma concentrations of mianserin and its major active metabolite, desmethylmianserin.
Topics: Adult; Age Factors; Aged; Chromatography, High Pressure Liquid; Depression; Female; Humans; Male; Mi | 1993 |
Prediction of plasma concentrations of mianserin and desmethylmianserin at steady state from those after an initial dose of mianserin.
Topics: Adult; Aged; Animals; Depression; Female; Humans; Male; Mianserin; Middle Aged | 1993 |
Mirtazapine--a new antidepressant.
Topics: Antidepressive Agents, Tricyclic; Clinical Trials as Topic; Depression; Histamine H1 Antagonists; Hu | 1996 |
Effects of antidepressants on phencyclidine-induced enhancement of immobility in a forced swimming test in mice.
Topics: Animals; Antidepressive Agents; Depression; Desipramine; Hallucinogens; Hydroxyindoleacetic Acid; Ma | 1997 |
Effects of thioridazine, an inhibitor of CYP2D6, on the steady-state plasma concentrations of the enantiomers of mianserin and its active metabolite, desmethylmianserin, in depressed Japanese patients.
Topics: Antidepressive Agents, Second-Generation; Cytochrome P-450 CYP2D6 Inhibitors; Depression; Enzyme Inh | 1997 |
Correlation between steady-state plasma concentrations of mianserin and trazodone in depressed patients.
Topics: Antidepressive Agents, Second-Generation; Cytochrome P-450 CYP2D6; Depression; Female; Humans; Male; | 1998 |
[Treatment of fibromyalgia].
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Antidepressive Agents, Second-Generation; Anxiety Di | 1998 |
Serotonin syndrome with mirtazapine-fluoxetine combination.
Topics: Adrenergic alpha-Antagonists; Aged; Antidepressive Agents, Tricyclic; Depression; Drug Interactions; | 1998 |
[Mirtazapin--fast and strong effects].
Topics: Antidepressive Agents, Tricyclic; Depression; Fluoxetine; Humans; Mianserin; Mirtazapine; Selective | 1998 |
Mirtazapine-induced mania in a case of poststroke depression.
Topics: Aged; Antidepressive Agents, Tricyclic; Bipolar Disorder; Cerebrovascular Disorders; Depression; Hum | 1999 |
Clinical pharmacology of mirtazapine: revisited.
Topics: Agranulocytosis; Antidepressive Agents, Tricyclic; Anxiety; Depression; Humans; Mianserin; Mirtazapi | 1999 |
[Mirtazapine--the new standard].
Topics: Antidepressive Agents, Tricyclic; Depression; Depressive Disorder; Humans; Mianserin; Mirtazapine | 1999 |
Does mirtazapine enhance serotonergic neurotransmission in depressed patients?
Topics: Adult; Antidepressive Agents, Tricyclic; Depression; Female; Humans; Male; Mianserin; Middle Aged; M | 2000 |
Hypertensive urgency induced by an interaction of mirtazapine and clonidine.
Topics: Adrenergic alpha-Agonists; Adrenergic alpha-Antagonists; Adult; Antidepressive Agents; Antihypertens | 2000 |
[Macroglossia and tongue papular injury due to mirtazapine treatment].
Topics: Adult; Antidepressive Agents, Tricyclic; Depression; Humans; Macroglossia; Male; Mianserin; Mirtazap | 2000 |
The differential effects of calcium channel blockers in the behavioural despair test in mice.
Topics: Animals; Antidepressive Agents; Calcium Channel Blockers; Clomipramine; Clonidine; Cyproheptadine; D | 2000 |
Economic impact of using mirtazapine compared to amitriptyline and fluoxetine in the treatment of moderate and severe depression in the UK.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amitriptyline; Antidepressive Agents, Tricyclic; Cost-Be | 2000 |
Treatment of hot flushes with mirtazapine: four case reports.
Topics: Adult; Antidepressive Agents, Tricyclic; Depression; Female; Hot Flashes; Humans; Mianserin; Middle | 2000 |
Mirtazapine for treatment of depression and comorbidities in Alzheimer disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Antidepressive Agents, Tricyclic; Comorbidity; Depressio | 2001 |
Availability of learned helplessness test as a model of depression compared to a forced swimming test in rats.
Topics: Amoxapine; Animals; Antidepressive Agents; Behavior, Animal; Clomipramine; Depression; Disease Model | 2001 |
[Interference in the serotoninergic and noradrenergic system. Faster out of depression].
Topics: Adrenergic alpha-Antagonists; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricy | 2001 |
Chronic treatment with imipramine or mirtazapine antagonizes stress- and FG7142-induced increase in cortical norepinephrine output in freely moving rats.
Topics: Animals; Anti-Anxiety Agents; Antidepressive Agents, Tricyclic; Anxiety; Carbolines; Cerebral Cortex | 2002 |
In the rat forced swimming test, NA-system mediated interactions may prevent the 5-HT properties of some subacute antidepressant treatments being expressed.
Topics: Adrenergic alpha-Antagonists; Animals; Antidepressive Agents; Biogenic Monoamines; Brain; Depression | 2002 |
Severe serotonin syndrome induced by mirtazapine monotherapy.
Topics: Aged; Antidepressive Agents, Tricyclic; Depression; Humans; Male; Mianserin; Mirtazapine; Serotonin | 2002 |
Acute and chronic hypertensive headache and hypertensive encephalopathy.
Topics: Acute Disease; Antidepressive Agents; Antihypertensive Agents; Anxiety; Arterioles; Cerebral Arterie | 2002 |
Effect of chronic amphetamine administration on the behaviour of rats in the open field apparatus: reversal of post-withdrawal depression by two antidepressants.
Topics: Amitriptyline; Animals; Antidepressive Agents; Behavior, Animal; Depression; Dextroamphetamine; Huma | 1978 |
Leucopenia in association with mianserin treatment.
Topics: Aged; Chronic Disease; Depression; Dibenzazepines; Female; Humans; Leukopenia; Mianserin | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
A new depression scale designed to be sensitive to change.
Topics: Adolescent; Adult; Aged; Amitriptyline; Clomipramine; Depression; England; Female; Humans; Male; Map | 1979 |
[Treatment of depressed out-patients with mianserin (author's transl)].
Topics: Ambulatory Care; Depression; Dibenzazepines; Female; Humans; Male; Mianserin | 1979 |
Video-analytic study of manual kinesics and its lateralization in the course of treatment of depressive syndromes.
Topics: Amitriptyline; Depression; Humans; Interview, Psychological; Kinesics; Mianserin; Videotape Recordin | 1979 |
Novel antidepressants and the biogenic amine hypothesis of depression. The case for iprindole and mianserin.
Topics: Adjustment Disorders; Affective Disorders, Psychotic; Amitriptyline; Biogenic Amines; Brain; Depress | 1979 |
Effect of mianserin on cardiac conduction.
Topics: Adult; Depression; Dibenzazepines; Female; Heart; Heart Conduction System; Hemodynamics; Humans; Mal | 1979 |
Depression: a new animal model sensitive to antidepressant treatments.
Topics: Animals; Antidepressive Agents; Depression; Disease Models, Animal; Electroshock; Humans; Iprindole; | 1977 |
Two more new antidepressives: mianserin and butriptyline.
Topics: Depression; Dibenzazepines; Dibenzocycloheptenes; Humans; Mianserin | 1977 |
Clinical experience with Org GB94 (mianserin hydrochloride), a new tetracyclic antidepressant.
Topics: Adolescent; Adult; Age Factors; Aged; Antidepressive Agents; Bipolar Disorder; Depression; Dibenzaze | 1978 |
[Study report on the lack of interaction between mianserine and noradrenaline in man].
Topics: Antidepressive Agents, Tricyclic; Depression; Dibenzazepines; Drug Evaluation; Drug Interactions; Hu | 1978 |
Mass fragmentographic assay of nanogram amounts of the antidepressant drug mianserin hydrochloride (Org GB 94) in human plasma.
Topics: Adult; Depression; Dibenzazepines; Gas Chromatography-Mass Spectrometry; Humans; Kinetics; Male; Mia | 1977 |
Poisoning with antidepressants.
Topics: Antidepressive Agents; Depression; Dibenzazepines; Family Practice; Flupenthixol; Humans; Mianserin; | 1977 |
Mianserin hydrochloride: a novel antidepressant.
Topics: Adjustment Disorders; Amitriptyline; Depression; Dibenzazepines; Drug Evaluation; Female; Humans; Ma | 1976 |
[Symptoms of Creutzfeldt-Jakob disease during mianserin therapy].
Topics: Aged; Creutzfeldt-Jakob Syndrome; Depression; Epilepsy; Epilepsy, Tonic-Clonic; Female; Humans; Male | 1991 |
[Lithium augmentation for mianserin-resistant depression in the elderly].
Topics: Aged; Depression; Drug Resistance; Drug Therapy, Combination; Humans; Lithium; Male; Mianserin | 1992 |
Effects of MK-801 and antidepressant drugs in the forced swimming test in rats.
Topics: Animals; Antidepressive Agents; Citalopram; Depression; Dizocilpine Maleate; Haloperidol; Imipramine | 1992 |
Depression in Alzheimer's disease significantly improved under treatment with mianserine.
Topics: Aged; Alzheimer Disease; Depression; Female; Humans; Mianserin | 1991 |
Comparison of the effects of mianserin and its enantiomers and metabolites on a behavioral screen for antidepressant activity.
Topics: Analysis of Variance; Animals; Antidepressive Agents; Behavior, Animal; Conditioning, Operant; Depre | 1991 |
[Depression in late life].
Topics: Age Factors; Aged; Antidepressive Agents; Depression; Electric Stimulation Therapy; Humans; Japan; M | 1991 |
Mianserin as a cause of arthritis.
Topics: Arthritis; Depression; Humans; Joint Diseases; Mianserin; Pain | 1991 |
Lack of tolerance to imipramine or mianserine in two animal models of depression.
Topics: Amphetamine; Animals; Anorexia; Behavior, Animal; Depression; Disease Models, Animal; Dose-Response | 1990 |
[Determination of 3-methoxy-4-hydroxyphenyethylene-glycol and its urinary conjugates. Value in the diagnosis and therapeutic follow-up of depression].
Topics: Clomipramine; Depression; Drug Therapy, Combination; Follow-Up Studies; Glycols; Humans; Hydroxyindo | 1988 |
Hepatic injury caused by mianserin.
Topics: Chemical and Drug Induced Liver Injury; Depression; Female; Humans; Liver; Male; Mianserin; Middle A | 1989 |
The efficacy of mianserin (Lerivon) in various forms of depression.
Topics: Adult; Antidepressive Agents, Tricyclic; Depression; Dose-Response Relationship, Drug; Female; Human | 1989 |
Psychiatrists and Alzheimer's disease.
Topics: Alzheimer Disease; Circadian Rhythm; Cognition; Dementia; Depression; Diagnosis, Differential; Human | 1989 |
Mianserin plasma levels and clinical response in primary depression.
Topics: Adult; Aged; Depression; Female; Humans; Male; Mianserin; Middle Aged; Psychiatric Status Rating Sca | 1986 |
Mianserin in the treatment of elderly depressives.
Topics: Aged; Depression; Humans; Mianserin | 1987 |
[2d-generation antidepressive agents].
Topics: Depression; Humans; Mianserin; Serotonin Antagonists | 1987 |
Mianserin.
Topics: Antidepressive Agents, Tricyclic; Depression; Dibenzazepines; Humans; Mianserin; Suicide | 1985 |
Mianserin and agranulocytosis.
Topics: Aged; Agranulocytosis; Depression; Dibenzazepines; Female; Humans; Mianserin | 1986 |